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I
Abstract
Proteolytic release of ectodomains at the cell membrane, termed ectodomain shedding, is 
an irreversible post-translational mechanism to regulate protein function. Members of the 
a disintegrin and metalloprotease (ADAM) family are key enzymes in shedding of recept-
ors and ligands and, hence, inf luence cell signaling.
Conditional deletion of ADAM10 in murine tissues, such as brain or skin, indicates an 
essential role for the protease in both organ development and tissue integrity. However, 
the function of ADAM10 in liver physiology in vivo is largely unknown.
We show that in mice with a liver specific deletion of ADAM10 tissue homeostasis in the 
liver is impaired.
Development of the biliary tree, which is dependent on the ADAM10 substrate Notch, 
was not altered in our mice. Still, mice lacking ADAM10 in the liver developed spontan-
eous necrosis to various degrees. Interestingly, the liver injury did not cause an increase in 
pro-inf lammatory cytokines. Despite regeneration of the necrotic areas, we observed an 
accumulation of proliferating liver progenitor cells and a persistent activation of hepatic 
stellate cells leading to a striking liver fibrosis. We detected, in accordance with these find-
ings, enhanced liver progenitor cell mitogen signaling in a liver progenitor cell line in the 
absence of ADAM10 activity.
Our  results  demonstrate  that  ADAM10-mediated  proteolytic  processing  seems  to  be 
essential in the termination of liver progenitor cell-driven regenerative processes that, if 
deregulated, lead to chronic liver disease. They furthermore underline the importance of 
irreversible post-translational modifications for the maintenance of tissue homeostasis.
II
Zusammenfassung
Die proteolytische Abspaltung von extrazellulären Domänen an der Zelloberf läche, auch 
als  Ectodomain-Shedding bezeichnet, ist ein unumkehrbarer post-translationeller Mechanis-
mus zur Regulation der Proteinfunktion. Mitglieder der “A disintegrin and metallopro-
tease”  (ADAM)  Familie  sind  für  das  Ectodomain-Shedding von  vielen  Rezeptoren  und 
Liganden verantwortlich und beeinf lussen so die zelluläre Kommunikation.
Durch gewebsspezifische Knock-Outs von ADAM10, in Gehirn oder Haut von Mäusen, 
konnte der Protease bereits eine wichtige Funktion sowohl in der Organentwicklung als 
auch in der Gewebsintegrität zugeordnet werden. Die in vivo Funktion von ADAM10 in 
der Leber ist jedoch größtenteils unbekannt.
Wir zeigen in dieser Studie, dass in Mäusen mit einem leberspezifischen Knock-Out von 
ADAM10 die Gewebsintegrität der Leber beeinträchtigt ist.
Die Entwicklung des Gallengangsystems, für die das ADAM10 Substrat Notch benötigt 
wird, war in unseren Mäusen nicht beeinträchtigt. Jedoch entwickelten Mäuse mit einem 
leberspezifischen  ADAM10  Knock-Out  spontane  Nekrosen,  die  unterschiedlich  stark 
ausgeprägt waren. Interessanterweise bewirkte der Leberschaden keine Erhöhung von ent-
zündungsfördernden Zytokinen. Trotz Reparatur der nekrotischen Gebiete beobachteten 
wir eine Anhäufung von sich vermehrenden Lebervorläuferzellen und eine damit einher-
gehende andauernde Aktivierung von Ito-Zellen,  die  zu einer  markanten Leberfibrose 
führten. In Übereinstimmung mit diesen Beobachtungen konnten wir in einer Zelllinie 
von Lebervorläuferzellen zeigen, dass die Hemmung der ADAM10 Aktivität zu einem 
erhöhten Mitogensignal führt.
Unsere Ergebnisse weisen darauf hin, dass die proteolytische Spaltung durch ADAM10 
wichtig ist für die Beendung von Lebervorläuferzell-abhängiger Regeneration, die unre-
guliert zu chronischen Lebererkrankungen führt. Sie betonen außerdem die Bedeutung 
von unumkehrbaren post-translationellen Modifizierungen für die Aufrechterhaltung der 
Gewebsintegrität.
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1 Introduction
1 Introduction
1.1 Liver
The liver has always held a fascination for mankind. In ancient Mesopotamia hepatoscopy, 
the art of liver augury, was practiced to get signs of the gods' intentions. The Greeks even 
believed the liver to be the seat of life and passion. However, since the end of the nine-
teenth century the liver has been in the focus of scientists for a different reason: it's enorm-
ous potential to regenerate [1]. After loss of 2/3 of the liver, regrowth of the liver to its ori-
ginal mass takes only 5-7 days in rodents and 8-15 days in humans. The underlying mech-
anisms will be discussed in more detail in chapter 1.1.2.
The liver is  the largest internal organ, both in mice and men. It executes essential func-
tions including bile production, metabolism of dietary compounds, detoxification, regu-
lating glucose levels via glycogen storage, and contributing to blood homeostasis by secret-
ing serum proteins and clotting factors. The liver, through regulating levels of plasma gluc-
ose and ammonia, is essential for brain function. Liver failure can therefore lead to hepatic 
encephalopathy and ultimately to coma [2].
1.1.1 Development, cellular architecture and function
Five cell types are predominantly found in the adult liver. Firstly, the hepatocytes that form 
the liver parenchymal tissue and make up the main mass of the liver. Secondly, the biliary 
epithelial cells also known as cholangiocytes that line the bile ducts. Furthermore there are 
the liver-resident macrophages, the Kupffer cells, and the hepatic stellate cells. Finally, the 
endothelial cells that line the blood vessels. The sinusoidal endothelial lining has a specific 
fenestration pattern and is separated from the hepatocytes by the space of Disse (Figure
1.3) [3].
Through fate mapping experiments the embryonic development of the liver was shown to 
proceed in several steps [4]. At embryonic day of gestation 9 the hepatic diverticulum is 
formed out of the ventral foregut endoderm. The anterior portion of the hepatic divertic-
ulum gives rise to the hepatoblasts, bipotential progenitors that can develop into hepato-
cytes  and cholangiocytes. Hepatoblasts  express  genes found in mature hepatocytes (alb, 
coding for Albumin) and genes found in mature cholangiocytes (krt19, coding for cytoker-
atin 19) as well as fetal liver genes (afp, coding for alpha-fetoprotein). The posterior part of 
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the hepatic diverticulum later on develops into the gall bladder and the extrahepatic bile 
ducts. At embryonic day of gestation 9.5 the liver bud is formed by hepatoblasts (see Fig-
ure 1.1). 
Figure 1.1: Early liver development
Depicted are early stages of murine embryo development. The endoderm is formed during gastrulation between 
embryonic day of gestation  6.5 -  embryonic day of gestation  7.5 and starts developing into foregut (fg), midgut 
(mg), and hindgut (hg). At  embryonic day of gestation  9 the liver diverticulum (ld) is formed from the ventral 
foregut and expands into the liverbud (lb) by  embryonic day of gestation  10. Endoderm tissue is highlighted in 
yellow, the liver in red, and the gallbladder in green. e= embryonic day of gestation 
Modified from [3] (reprint permitted with citation)
From embryonic day of gestation 10 to embryonic day of gestation 15 the liver experi-
ences a growth spurt due to vascularization and colonialization by hematopoietic cells, 
turning the liver into the major fetal hematopoietic organ.
Figure 1.2: Late liver development
The schematic shows the steps of bile duct formation during development. Around embryonic day of gestation 13 
hepatoblasts surrounding the portal vein mesenchyme adopt a biliary fate. This layer duplicates and by ductal plate  
remodeling focal dilations in the bi-layer arise. From embryonic day of gestation 17 to the perinatal period the focal 
dilations develop into bile ducts, that are surrounded by portal mesenchyme. The rest of the bi-layer regresses and 
hepatocytes in the parenchyma mature. e= embryonic day of gestation
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Around embryonic day of gestation 13 gradual differentiation of the hepatoblasts begins. 
Hepatoblasts that are in proximity to the portal vein start transitioning into cholangiocytes 
whereas the majority of hepatoblasts differentiates into hepatocytes forming the paren-
chymal tissue. This process is also referred to as ductal plate remodeling (see  Figure 1.2) 
[5].
Signals from the periportal mesenchyme induce this development. Evidently, expression 
of Notch and the Notch ligand Jagged-1 are important for proper bile duct formation. 
Activation of Notch2 on hepatoblasts through Jagged-1, expressed on mesenchymal cells, 
is required for cholangiocyte differentiation [6]. Mice deficient for Notch2 or Notch1 and 
Notch2 show an altered three-dimensional structure of the biliary tree with diminished 
bile ducts. Over-expression of Notch1 intracellular domain leads to a hyper-branching of 
the biliary network and to formation of cholangiocarcinoma [7, 8]. Paucity of bile ducts 
can also be observed in human patients suffering from Alagille syndrome. These patients 
have autosomal dominant mutations in either  notch or  jag1 and therefore fail to correctly 
resolve the ductal plate during development [9].
Figure 1.3: Schematic of adult liver structure and zoning
Depicted are all 5 major liver cell types: hepatocytes, cholangiocytes, Kupffer cells, stellate cells, and endothelial  
cells. Additionally, central features like portal triad, central vein, or space of Disse are indicated. Division in zones is 
based on a metabolic perspective.
Modified from [10] (open source)
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Stellate cells, Kupffer cells and the endothelial cells derive from the mesoderm and will not 
be discussed here in detail [3].
The liver can be separated in three zones. Zone 1 contains the portal triad consisting of 
portal vein, hepatic artery and bile duct. The central vein lies in zone 3. The liver paren-
chyma in between zone 1 and 3 is denominated zone 2 (Figure 1.3). The portal triad is 
located in the middle of hepatic plates, cell sheets of hepatocytes, that are divided by sinus-
oid spaces connected to blood vessels. Via the basal side the hepatocytes take up metabol-
ites and toxins from the blood in the sinusoids. On the apical side the hepatocytes secrete 
primary bile acids into bile canaliculi, small grooves in the cell surface, from which it f lows 
into the canals of Hering and finally via the bile ducts to the gall bladder [3].
1.1.2 Liver cell death and liver tissue homeostasis
The liver, like most organs, has a steady turnover of cells which is, however, comparably 
low. Only 0.05% of hepatocytes in healthy individuals are, at any given time, undergoing 
apoptosis.  Apoptosis is  mainly occurring in zone 3,  indicating an aging of hepatocytes 
from zone 1 to zone 3 [11]. However, cell death in the liver can occur massively through 
toxin-induced injury or bacterial  or parasitic  infections.  Liver damage is  also mediated 
through lifestyle-dependent chronic diseases like alcoholic liver disease or non-alcoholic 
fatty liver disease. Classically, cell death is  divided into necrosis and apoptosis, but also 
other forms of cell  death are found like necroptosis  and autophagy  [12].  Necrotic  cell 
death in the liver is found mostly following toxic-induced liver injury [13]. But often nec-
rosis and apoptosis occur side by side in liver disease as described for alcoholic liver disease 
[14].
Several serum proteins serve as biomarkers to detect liver damage and cell death. The most 
common biomarker for diagnosis of liver disease is alanine transaminase (formerly known 
as glutamate-pyruvate transaminase). Alanine transaminase is highly specific for hepatocel-
lular damage. Alanine transaminase levels in the blood are upregulated upon acute (500 – 
20 000 U/l, mice and men) or chronic (120 – 500 U/l, mice and men) liver damage and 
can be correlated to chronic disease progression. However, in cirrhotic patients alanine 
transaminases are not necessarily upregulated. Aspartate aminotransferase (formerly known 
as glutamic oxaloacetic transaminase) can be used as a serum marker for liver injury but 
lacks specificity due to expression in other tissues like heart and kidney.  [15]. Levels of 
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alkaline phosphatase can be used to detect cholestatic liver damage found for example in 
patients with primary biliary cirrhosis [16].
For  liver  regeneration  to  progress  smoothly  a  coordinated  response  of  immune  cells, 
including macrophages, T-cells, and eosinophils, is required. Macrophages are recruited to 
injured hepatocytes and initiate the inf lammatory response through release of pro-inf lam-
matory cytokines like tumor necrosis factor α or interleukin-6. Macrophages can act pro-
fibrotically  by activating hepatic stellate  cells  but also help resolve fibrosis by inducing 
apoptosis in hepatic stellate cells and secreting matrix metalloproteases that degrade the 
extracellular  matrix  [17,  18].  Liver  regeneration  is  strongly  disabled  in  diseases  like 
advanced cirrhosis or hepatitis leading to liver failure with fatal consequences. The only 
lasting clinical treatment is organ transplantation. Due to donor sparsity and procedural 
complication alternatives to transplantation are desperately needed. 
Mechanisms of liver regeneration are dependent on the damage and are considered mutu-
ally exclusive. The primary mode is through replication of existing mature hepatocytes by 
inducing mitosis and increasing cell volume of present hepatocytes. In animal models this 
situation can be mimicked by partial hepatectomy. This process is tightly regulated and 
leads to restoration of the original liver mass [19]. However, in cases of severe fibrosis in 
chronic sickness, when the regenerative potential of hepatocytes is impaired or depleted, 
or if hepatocyte proliferation is inhibited by toxins, another mechanism is initiated. Liver 
progenitor cells (also known as hepatic progenitor cells or oval cells) are activated, prolifer-
ate, and differentiate to mature liver cells [20].
1.1.3 Liver progenitor cells
Due to their bipotential capacity it is suggested that liver progenitor cells derive from fetal 
hepatocytes and reside in very small numbers in a niche close to the canals of Hering until  
they are activated [21]. It has been shown that the cells responsible for regeneration after 
chronic  liver  injury  are  leucine-rich  repeat-containing  G-protein  coupled  receptor 5 
(Lgr5) positive, as are stem cells in the intestine that drive constitutive self-renewal, under-
lining their progenitor status. However, Lgr5+ cells are not detectable under non-diseased 
conditions  [22].  Despite  many  studies  describing  liver  progenitor  cells,  they  are  not 
acknowledged by all and alternative theories imply a dedifferentiation of either cholangio-
cytes or hepatocytes that then differentiate into hepatocytes or cholangiocytes, respectively 
[2].
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For appropriate differentiation of liver progenitor cells an interplay of Notch and Wnt sig-
naling is necessary. Wnt signaling drives differentiation of liver progenitor cells towards a 
hepatocytic fate whereas Notch signaling leads to differentiation into cholangiocytes. It 
could be shown that through phagocytosis of hepatocyte debris macrophages upregulate 
wnt expression and activate Wnt-signaling in nearby liver progenitor cells. Furthermore, 
the Notch pathway inhibiting ubiquitin ligase Numb is activated by β-catenin presenting a 
decisive cross-section of both lineage specifying pathways [23].
Known mitogens of liver progenitor cells are hepatocyte growth factor and tumor necrosis 
factor superfamily member 12 (also known as tumor necrosis factor-like weak inducer of 
apoptosis).
Hepatocyte  growth  factor  binds  to  its  receptor  c-Met  and  induces  c-Met  autophos-
phorylation on tyrosine residues  [24]. In a murine model inducing liver progenitor cell-
driven regeneration it was shown that mice with a Met deficiency died from liver failure.  
Liver failure was proposed to result from ineffective progenitor cell mediated regeneration, 
since it was demonstrated that loss of c-Met leads to a decreased oval cell pool and also 
affects migration and differentiation abilities of oval cells [25].
Tumor necrosis factor superfamily member 12 is released by macrophages in chronic liver 
injury.  Tumor  necrosis  factor  superfamily  member  12  activates  the  NFκB  pathway 
through its receptor tumor necrosis factor receptor superfamily member 12a (also Fn14) 
leading to liver progenitor cell activation and proliferation [26]. 
But also the microenvironment and, within it, interactions with other cells are essential for 
liver progenitor cell-driven regeneration [20]. Especially the cross-talk between liver pro-
genitor cells and hepatic stellate cells is of interest since it can either lead to wound healing  
or progressive chronic liver injury. One key regulator of the hepatic stellate cell/ liver pro-
genitor cell cross-talk is lymphotoxin-β, a member of the tumor necrosis factor family. 
Lymphotoxin-β is  expressed on activated liver  progenitor  cells  in  chronic  liver  injury. 
Lymphotoxin-β binds to the lymphotoxin-β receptor, which is expressed on hepatic stel-
late cells. This interaction leads to side-by-side migration of liver progenitor cells and hep-
atic stellate cells to sites of injury and might increase fibrogenesis [27].
Due to their plasticity and differentiation potential liver progenitor cells are considered 
interesting therapeutic targets as an alternative to orthopic liver transplantation. However, 
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despite all recent advances in liver progenitor cell research, knowledge about the complex 
regulatory mechanisms of liver progenitor cells is still limited and needs to be expanded.
Although liver progenitor cells are known to contribute to liver regeneration, a prolonged 
liver progenitor cell response leads to fibrosis. Additionally, deregulation of differentiation 
and proliferation of liver progenitor cells can cause malignant transformation to tumor-ini-
tiating cells [28]. It has been reported that progenitor cells can progress to a malignant 
status, dependent on autocrine interleukin-6 signaling [29].
1.1.4 Liver fibrosis
During liver repair extracellular matrix is deposited. This is a transient and reversible pro-
cess in acute or limited injuries.  However in chronic liver diseases extracellular matrix 
accumulates and progressively substitutes liver parenchyma leading to fibrosis. Several pat-
terns of fibrosis can be distinguished and depend on the underlying disease.
Figure 1.4: Fibrotic patterns
Bridging fibrosis  is characterized by fibrotic septa spanning from portal regions to central regions. The typical  
“chicken-wire” pattern from extracellular matrix deposition around hepatocytes is found in pericellular fibrosis. In 
biliary fibrosis septa connect the portal regions whereas in centrolobular fibrosis the central regions are connected  
by fibrotic septa.
Formation of portal central fibrotic septa is classified as bridging fibrosis.  Infection with 
hepatitis B or C virus lead to bridging fibrosis. Perisinusoidal or pericellular fibrosis can be 
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distinguished by a typical  “chicken-wire” pattern that  results  from extracellular matrix 
deposition in the space of Disse around sinusoids or hepatocytes. Typical triggers are alco-
holic liver disease and non-alcoholic fatty liver disease. Lastly, there are biliary fibrosis, 
consisting of fibrotic septa spanning from portal region to portal region, and centrolobular 
fibrosis with fibrotic septa from central area to central area (see Figure 1.4) [30].
Even though advancement of liver fibrosis to liver cirrhosis can be slow, it leads to a high 
risk of mortality. On top of being already a high risk in itself, cirrhosis can trigger develop-
ment of hepatocellular carcinoma (Figure 1.5) [31]. 
Figure 1.5: Progressive liver disease
Chronic injuries like viral infections or alcohol abuse cause inflammation and parenchymal cell death. In the process  
of tissue repair extracellular matrix is deposited. If damage persists the extracellular matrix accumulates leading to 
fibrosis and consequently to cirrhosis, at which step liver failure and portal hypertension occur. Although fibrosis  
can be rapidly resolved if the cause is eliminated this is not the case for cirrhosis. Once cirrhosis is established only  
regression but not resolution is possible. Transplantation is currently the only long-term treatment option for liver 
failure. Although liver cirrhosis in itself is a cause of mortality, it can additionally contribute to development of  
hepatocellular carcinoma.
The primary effector cells in fibrosis are hepatic stellate cells. They usually reside in an 
inactive or quiescent state in the space of Disse. Upon liver injury hepatic stellate become 
activated. Activation takes place in two phases: initiation and perpetuation. The first phase 
starts shortly after injury occurs. It is driven by signals from Kupffer cells and endothelial  
cells as well as exposure to debris from damaged hepatocytes. This leads to altered gene 
expression and altered responsiveness to cytokines. Proteins affected through transcrip-
tional  changes are collagen I,  α-smooth muscle  actin,  transforming growth factor  β 1, 
transforming growth factor  β-receptor, matrix metalloprotease-2, and tissue inhibitor of 
metalloprotease 1 and 2 [32]. After the first priming phase a second phase finalizes activa-
tion. Hepatic stellate cells lose their vitamin-A rich lipid droplets completely, proliferate, 
show greater contractility and produce great amounts of extracellular matrix (Figure 1.6) 
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[26]. Composition of the extracellular matrix is different compared to healthy livers. The 
normally  present  collagens  IV  and  VI  are  replaced  by  collagens  I  and  III  as  well  as 
fibronectin [30].  Proliferation of hepatic stellate  cells  is  driven mainly by transforming 
growth factor β and epidermal growth factor. These growth factors are also proteolytically 
released for paracrine stimulation of regenerative hepatocyte proliferation [33, 34].
Fibrosis is part of the wound healing process in the liver. It has been shown that fibrosis 
leads to more resistance to subsequent acute injury and that collagen I protects hepatocytes 
against toxic damage. Only if resolution of fibrosis is dysregulated and excessive amounts 
of extracellular matrix are deposited tissue function is altered and becomes pathologic [18].
Figure 1.6: Schematic of cellular events in liver fibrosis
In case of chronic injury in the liver hepatic stellate cells, residing in the space of Disse, get activated through signals  
from Kupffer cells  and endothelial cells.  This  leads to loss of their lipid droplets, changes in morphology, and 
deposition of extracellular matrix. In addition hepatocytic microvilli are lost as well as endothelial fenestration.
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1.2 A disintegrin and metalloproteases (ADAMs)
Proteins are known to be tightly regulated at the transcriptional and translational level. 
However, they can also be modified post-translationally, affecting protein stability or func-
tion. One post-translational modification is proteolytic processing. The release of mem-
brane-bound proteins by proteolytic cleavage is termed ectodomain shedding. Members of 
the a  disintegrin and metalloprotease (ADAM) family  are key enzymes in  ectodomain 
shedding.
ADAMs belong to the metzincins, a superfamily of zinc-based proteinases  [35]. Within 
this  superfamily  the  ADAMs  are  found  in  the  adamalysin  subfamily 
(http://http://merops.sanger.ac.uk/; [36]). ADAMs are either secreted or type I single-pass 
transmembrane proteins of approximately 750 amino acids (aa) length. ADAMs have been 
detected in many species ranging from nematodes (C. elegans) to vertebrates (M. musculus,  
H sapiens) [37]. 
1.2.1 Domain structure of ADAMs
ADAMs have a very conserved modular layout as shown in the schematic in  Figure 1.7. 
All ADAMs are synthesized in the endoplasmic reticulum with an N-terminal signal pep-
tide  regulating  transit  through  the 
secretory  pathway.  ADAMs  are 
glycosylated  co-translationally  [38]. 
C-terminal to the signal peptide is a 
pro-domain  which  acts  as  an 
intramolecular  chaperone  [39,  40]. 
The  pro-domain  further  inhibits 
activity  of  the  metalloprotease 
domain via a cysteine-switch mech-
anism.  It  is  removed intracellularly 
by pro-protein convertases like furin 
during  maturation  in  the  trans-
Golgi compartment [41, 42]. Several 
studies  have shown that recombin-
ant  pro-domains  of  ADAMs  can 
very  selectively  inhibit  the  active 
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Figure  1.7:  Domain  structure  of  an  ADAM  (based  on 
ADAM10)
ADAMs are secreted or, as depicted here, type I transmembrane 
proteins consisting of a cytosolic, a transmembrane, a cysteine-
rich, a disintegrin, in some cases an epidermal growth factor-like 
(not  shown),  and  a  metalloprotease  domain.  ADAMs  are 
synthesized as zymogens with a pro-domain (not shown),  that 
serves both as an intramolecular chaperone and as inhibitor of 
the protease.
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mature form  [43,  44].  Subsequent  to the pro-domain ADAMs have a  metalloprotease 
domain succeeded by a disintegrin-like domain that is considered to mediate interactions 
between ADAMs and integrins through a 14 aa stretch named “disintegrin loop”  [45]. 
Following those domains are a cysteine-rich domain and an epidermal growth factor-like 
domain that is not found in ADAM10 or ADAM17 [46]. Structural analysis of the metal-
loprotease/disintegrin/cysteine-rich domains implies a C-shaped form with the cysteine-
rich domain facing the catalytic site of the metalloprotease domain [47]. Next is the trans-
membrane and finally the cytoplasmic domain which differs strongly in length (11-231 aa) 
and sequence between various ADAM family members [48].
1.2.2 Biological functions of ADAMs
There are 21 ADAMs in humans  that  are  considered functional.  Functionality  can be 
achieved  by  having  a  characteristic  active  site  in  the  metalloprotease  domain 
(HEXGHXXGXXHD) implying proteolytic activity. But also non-proteolytic ADAMs 
can be considered functional, with a role in protein folding and protein-protein interaction 
[49]. A classification based on functionality and tissue expression is shown in Figure 1.8.
Figure 1.8: Classification of the human ADAMs based on their functionality and tissue expression
The 21 functional members of the human ADAM family are grouped depending on proteolytic or non-proteolytic  
function as well as tissue specificity. The numbers of the respective ADAMs are listed below each group in the blue  
boxes. The for this study relevant protease ADAM10 is highlighted in orange.
Reprinted with permission from [50]
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Although all ADAMs share the described modular layout, a phylogentic analysis of the 
metalloprotease domain sequence shows a clear separation of ADAM10 and ADAM17 
from the other ADAMs but not from each other [50].
ADAMs have diverse functions e.g. in sperm-egg binding, ectodomain shedding, and as 
part of regulated intramembrane proteolysis. Only the two latter functions will be dis-
cussed here as these are the main functions for the investigated ADAM10. A graphic sum-
mary is shown in Figure 1.9. 
Ectodomain shedding has several functions, the first of which is releasing a ligand from the 
cell surface, enabling it to engage to its receptor either on the same cell (autocrine signal-
ing) or on other cells (paracrine signaling). Examples are epidermal growth factor receptor 
ligands like transforming growth factor  α and betacellulin  [51]. A second mechanism is 
shedding of receptors or ligands to abrogate juxtacrine cell-cell  signaling  [52]. Thirdly, 
receptors can be shed to act as decoy for soluble ligands, as reported for interleukin-1 
receptor 2 [53]. Shed receptors can also form complexes with ligands and induce signaling 
in cells only expressing the signal-transducing subunit, but not the receptor itself. A prime 
example for this mechanism is interleukin-6 trans-signaling where it also has been shown 
that signal quality differs depending on whether the receptor is membrane-bound or sol-
uble [54]. 
Ectodomain shedding is also a prerequisite for regulated intramembrane proteolysis. Pro-
teolytic cleavage of the ectodomain leads to the creation of a truncated substrate that can 
then  be  further  processed  by  intramembrane-cleaving  proteases.  Four  families  of  the 
intramembrane-cleaving proteases  are  known: S2P metalloproteases,  presenilin  aspartyl 
proteases,  SPP aspartyl  proteases,  and rhomboid serine  proteases  [55].  The intramem-
brane-cleaving  proteases  release  the  intracellular  domain  of  the  substrate  protein.  The 
intracellular domain can then translocate to the nucleus, bind to a transcription regulating 
complex, and affect gene transcription. Prominent proteins known to undergo regulated 
intramembrane proteolysis are Notch, amyloid precursor protein, and CD44 [56-58].
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Figure 1.9: ADAMs play a role in different signaling mechanisms
The schematic shows a selection of signaling processes that can be influenced by proteolytic activity of ADAMs.  
Mechanisms include shedding of ligands for autocrine (I) or paracrine (III) signaling, abolition of juxtacrine signaling 
by cleaving either ligand or receptor (II), proteolytic release of a receptor to either act as a decoy for a soluble  
ligand or to induce signaling at cells that express the signal-transducing subunit but not the receptor (IV), and  
triggering a sequential proteolytic cascade releasing an intracellular domain that induces gene transcription (V).
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1.3 A disintegrin and metalloprotease 10
ADAM10, also known as CD156c, kuzbanian protein homolog, or mammalian disinteg-
rin metalloprotease, is a 748 aa long type I transmembrane protein that was first identified 
in myelin membrane preparations from the bovine brain [59]. ADAM10 is encoded in the 
gene loci  15q21.3 in  humans  and 9:D in mice  [60,  61].  The murine  and the  human 
ADAM10 gene locus shows a highly conserved region upstream of the transcription initi-
ation site starting at -500 bp. Gene expression of ADAM10 can be repressed by its GC-
rich 5' untranslated region [62] or, specifically in the liver, by microRNA-122 [63].
1.3.1 Regulation of ADAM10
The domain structure of ADAM10 is as shown in  Figure 1.7. Of special interest is the 
cytoplasmic tail of ADAM10 that inf luences trafficking to selected areas, maturation, pro-
tein stability and activity. The C-terminus of ADAM10 contains two proline-rich putative 
src homolog 3 binding sites. In neurons it was shown that, by binding of synapse-associ-
ated protein 97 via the src homolog 3 domain, ADAM10 was transported to the post-syn-
aptic membrane  [64]. Furthermore, the src homolg 3 binding sites lead to a sorting of 
ADAM10 to basolateral tight-junctions in epithelial cells [65]. The cytoplasmic domain of 
ADAM10 has additionally an endoplasmic reticulum retention motif as well as an isoleu-
cine-glutamine (IQ) consensus site for calcium-independent binding of calmodulin that 
both inf luence protein trafficking to the cell surface and maturation [66, 67]. Several glyc-
osylation sites for N-glycans are found in the extracellular domain of ADAM10. Glyc-
osylated ADAM10 is protected from proteolytic degradation [38].
The C-terminus of ADAM10 is also a substrate for phosphorylation either by Protein 
kinase  C  α or  via  a  not  completely  unraveled  mechanism,  downstream  of  G-protein 
coupled receptors [68, 69].
Further regulatory processes affecting ADAM10 activity include proprotein convertases 
[42] as discussed earlier or natural inhibitors tissue inhibitor of metalloprotease 1 and 3 
[70]. ADAM10 itself can also be proteolytically processed by its own substrate meprin β 
leading to a soluble form of ADAM10 that is still enzymatically active and might have a 
different  substrate  spectrum [71,  72].  Other  proteases  shown  to  cleave  ADAM10  are 
ADAM9 and ADAM15 leading to regulated intramembrane proteolysis and resulting in an 
ADAM10 C-terminal fragment. The C-terminal fragment translocates to speckles in the 
14
1 Introduction
nucleus closely associated with two known nuclear speckle subtypes that are shown to loc-
alize to active transcription sites. This implies a role for ADAM10 in transcriptional con-
trol of genes [72, 73].
ADAM10 activity can also be regulated by localization to different membrane domains. 
Several groups demonstrated that ADAM10 is active after cholesterol depletion and activ-
ity  is  inhibited upon anchoring ADAM10 to cholesterol-rich domains [74,  75].  These 
findings  even  led  to  clinical  trials  with  cholesterol  lowering  statins  in  patients  with 
Alzheimer's disease that were, however, inconsistent in their results and showed either a 
protective effect [76] or no protective effect [77]. 
Membrane compartment localization of ADAM10 is yet interesting for another reason. It 
has been shown in several studies that ADAM10 interacts with multiple members of the 
tetraspanin family. Tetraspanin 12 and Tetraspanin 15 were both reported to regulate cel-
lular trafficking and increase ADAM10 maturation [78, 79]. In addition to that, it was 
demonstrated that tetraspanins inf luence ADAM10 localization to tetraspanin-enriched 
microdomains and thereby regulate  the activity  of ADAM10 towards several  substrates 
[80].
1.3.2 Biological functions of ADAM10
ADAM10 has until now more than 40 identified substrates [81]. The two most prominent 
targets of ADAM10 are amyloid precursor protein, making ADAM10 an interesting target 
in Alzheimer's disease, and the Notch receptors, that play important roles in development 
[82, 83]. ADAM10 also plays a role in other cell functions ranging from cell migration (N-
cadherin [68]) to immunity (CD23 [84]) to proliferation and apoptosis (CXCL16 [85] and 
FasL [86]).
This multitude of functions indicate that a tight regulation of ADAM10 is important and 
that deregulation of ADAM10 activity can lead to pathogenesis.  In Alzheimer's  disease 
amyloid precursor protein is cleaved by the beta-secretase BACE causing a specific trun-
cated  C-terminal  fragment  of  the  amyloid  precursor  protein  that  forms  the  toxic  Aβ 
plaques. ADAM10 is competing with the beta-secretase BACE for amyloid precursor pro-
tein and proteolytic processing by ADAM10 instead of BACE leads to the formation of a 
fragment that does not form toxic plaques [87].
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Notch is target of ADAM10, that, upon ligand binding, undergoes regulated intramem-
brane proteolysis. The released intracellular domain of Notch translocates to the nucleus 
where it forms a ternary complex with DNA binding proteins and regulates gene expres-
sion [88]. Target genes regulated by Notch include hairy and enhancer of split-1, a tran-
scriptional repressor that regulates proliferation and differentiation in embryogenesis, and 
Snail,  a  transcription  factor  inducing  epithelial  to  mesenchymal  transition  [89,  90]. 
Although ADAM17 is also reported to cleave Notch, it is not necessarily redundant to 
cleavage by ADAM10 and it has been proposed that ADAM10 Notch cleavage is ligand 
dependent and that ADAM17 cleaves Notch independent of ligand activation [91].
ADAM10 is, mainly through Notch-mediated functions, important for maintaining cell 
and  tissue  homeostasis  as  reported  for  B  cells,  intestinal  stem cells,  and  skin  [92-94]. 
Besides regulation of epidermal homeostasis via modulation of epidermal growth factor 
receptor signaling, ADAM10 also controls keratinocyte adhesion and migration through 
cleavage of E-cadherin and β-catenin signaling which, when deregulated, leads to eczemat-
ous dermatits [95, 96].
ADAM10 has also been shown  in vitro to cleave c-Met and abrogate hepatocyte growth 
factor-signaling [97]. However, the implication in liver physiology and pathology is greatly 
unknown.
Finally, ADAM10 overexpression has been described in many types of adenocarcinoma: 
breast cancer [98], colon carcinoma [99], gastric cancer [100], hepatocellular carcinoma 
[63],  leukaemia  [101],  prostate  cancer  [102],  oral  squamous  cell  carcinoma [103],  and 
uterus and ovarian cancer [104].
The many physiological roles of ADAM10 show that not only must ADAM10 be tightly 
regulated but it underlines the difficulty of developing therapeutic strategies that only tar-
get a certain aspect of ADAM10-mediated ectodomain shedding without deleterious side-
effects. Cell biological and biochemical studies already contributed greatly to knowledge 
of candidate substrates and effects on cell characteristics. But these approaches are limited 
and a more physiologic setting is needed to better understand the role of ADAM10 in 
development and disease and to develop efficient drugs [105].
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1.3.3 ADAM10 deficient mice
Thus, to study the function of ADAM10 more comprehensively in a physiological and 
pathological setting a mouse model lacking the protease was created. However these mice 
died early at embryonic day of gestation 9.5. The early lethality can be contributed to the 
ADAM10 target Notch since animals deficient in Notch1 and 2 show a similar phenotype 
[106].
To circumvent the early lethality, conditional knock-out mice were generated using the 
Cre/loxP site-specific recombination technology.  The Cre/loxP system originates  from 
the P1 phage and enables the targeted excision of DNA-sequences. The target sequence is  
f lanked by parallel oriented DNA recognition site, called loxP. A Cre-recombinase recog-
nizes those sites and excises the sequence in-between leading to a deletion. Strands are 
then rejoined by DNA ligase. [107]
Mice were generated with loxP sites f lanking exon 2 of the ADAM10 gene (see  Figure
1.10).  By  breeding  these  mice  with  mice  expressing  tissue-specific  Cre-recombinase 
ADAM10 deletion is limited to the targeted cells and embryonic lethality is avoided [108].
Figure 1.10: Recombination of ADAM10 with the Cre/loxP system
Exon 2 of ADAM10 is flanked by loxP sites (I). In the presence of a Cre-recombinase the parallel oriented loxP sites  
are recognized and bound (II). The sequence in between the two loxP sites is excised and the remaining loxP sites  
are ligated (III).
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1.4 Aim
ADAM10 was shown to be essential for organ development and tissue homeostasis but 
also to lead to pathologies if  deregulated. Yet, little is  known about ADAM10 in liver 
physiology and pathology. We therefore want to investigate the role of ADAM10 and its 
regulation in the liver.
To this aim we will generate mice deficient for ADAM10 in hepatoblasts and subsequently 
in hepatocytes, cholangiocytes and adult liver progenitor cells. We will examine these mice 
by  histological,  molecular  biological,  and  biochemical  analysis.  Data  from the  murine 
model will be complemented with in vitro experiments using the liver progenitor cell line 
BMOL. 
We hope to contribute to a better understanding of the consequences of proteolytic pro-
cessing by ADAM10 in the liver with the ultimate goal of providing new approaches to 
therapeutic interventions.
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2 Material & Methods
2.1 Material
2.1.1 Chemicals and recombinant proteins
William's E medium Sigma-Aldrich, Steinheim, Germany
Glutamine Sigma-Aldrich, Steinheim, Germany
FCS PAN Biotech, Aidenbach, Germany
Matrigel Corning, Bedford (MA), USA
GI254023X Iris Biotech, Marktredwitz, Germany
GW208264X Iris Biotech, Marktredwitz, Germany
Basic chemicals  were purchased from Carl Roth (Karlsruhe,  Germany), Sigma-Aldrich 
(Steinheim, Germany), or AppliChem (Darmstadt, Germany), unless otherwise stated. 
Table 1. Recombinant proteins
Name Supplier Product#
recombinant human insulin like growth factor-II (rhIGF-II) Immunotools, Friesoythe, Germany 11343573
recombinant murine epidermal growth factor (rmEGF) Immunotools, Friesoythe, Germany 12343406 
recombinant human Insulin Sigma-Aldrich, Steinheim, Germany I2643
recombinant human Tnfsf12 (rmTWEAK) Peprotech, Hamburg, Germany 310-06
recombinant murine hepatocyte growth factor (rmHGF) Peprotech, Hamburg, Germany 315-23
recombinant human transforming growth factor β 2 
(rhTGFβ2)
Immunotools, Friesoythe, Germany 11344751 
2.1.2 Primer
All oligonucleotides were synthesized by Sigma-Aldrich.
Table 2. Primers for genotyping and genomic DNA
Target Forward Primer (5'-3') Reverse Primer (5'-3') Expected 
bandsize
Adam10 ATGGATTGCCCTTTTATGTATTTA GCCGATGTGCCAGATGAGTG 262 bp (wt)
420 bp (flox)
ΔAdam10 TACAACCATGCCCAGCTTTTTAGT GCCGATGTGCCAGATGAGTG 700 bp
Cre CGAGTGATGAGGTTCGCAAG TGAGTGAACGAACCTGGTCG 390 bp
EYFP GGAGCGGGAGAAATGGATATG (wt)
AAGACCGCGAAGAGTTTGTC (tg)
AAAGTCGCTCTGAGTTGTTAT 600 bp (wt)
320 bp (tg)
Hbbt1 CCAATCTGCTCACACAGGATAGA
GAGGGCAGG
CCTTGAGGCTGTCCAAGTGATTC
AGGCCATCG
500 bp
rtTA CCATGTCTAGACTGGACAAGA CTCCAGGCCACATATGATTAG 600 bp
19
2 Material & Methods
Table 3. Primers for quantitative Real-Time PCR
Target Forward Primer (5'-3') Reverse Primer (5'-3') UPL# Sequence 
Reference
Acta2 GCATCCACGAAACCACCTAT AGGTAGACAGCGAAGCCAAG X13297
Actb TGGAATCCTGTGGCATCCATGAAA TAAAACGCAGCTCAGTAACAGTCCG NM_007393
Adam10 GGGAAGAAATGCAAGCTGAA CTGTACAGCAGGGTCCTTGAC 38 NM_007399
Col1a1 GAGCGGAGAGTACTGGATCG TACTCGAACGGGAATCCATC NM_007742
Cxcr4 TGGAACCGATCAGTGTGAGT GGGCAGGAAGATCCTATTGA 38 NM_009911
Cxcr7 AGAAGATGGTACGCCGTGTT ATCAGGCAGGGACACAAAGA BC015254.1
Id1 GCGAGATCAGTGCCTTGG CTCCTGAAGGGCTGGAGTC NM_010495
.2
Mmp2 CAGCAAGTAGATGCTGCC CAGCAGCCAGCCAGTC NM_008610
Mmp13 TTTGAGAACACGGGGAAGAC TGGGCCCATTGAAAAAGTAG NM_008607 
Spp1 CTCTGATCAGGACAACAAC CCTCAGAAGATGAACTCTC AF515708
Tgfb1 TGGAGCAACATGTGGAACTC GTCAGCAGCCGGTTACCA 72 NM_011577
Tgfb2 CCTTCGCCCTCTTTACATTG TTCGATCTTGGGCGTATTTC NM_009367
Timp1 GCAAAGAGCTTTCTCAAAGACC AGGGATAGATAAACAGGGAAACACT NM_001044
38
4.1/NM_011
59
3.2/NM_00
129
4280.2
Tnfrsf12a ATTCGGCTTGGTGTTGATG CCATGCACTTGTCGAGGTC NM_013749.
2
Tnfsf12 CAGGATGGAGCACAAGCAG GGCTGGAGCTGTTGATTTTG NM_011614.
3
Tuba1a1 CTGGAACCCACGGTCATC GTGGCCACGAGCATAGTTATT 88 NM_011653 
2.1.3 Antibodies
Table 4. Primary antibodies
Target Host species Dilution (application) Distributed by (Product#)
beta-actin mouse 1:10 000 (Immunoblot) Sigma-Aldrich (clone AC-15, A1978)
beta-actin rabbit 1:1 000 (Immunoblot) Sigma-Aldrich (A2066)
ADAM10 rabbit 1:1 000 (Immunoblot) Genetex (GTX63486)
GFP rabbit 1:1 000 (Immunoblot) Roche (11814460001)
TGFβRI rabbit 1:1 000 (Immunoblot) Santa Cruz (sc398)
TGFβRII mouse 1:1 000 (Immunoblot) Santa Cruz (sc17792)
SMAD2 rabbit 1:1 000 (Immunoblot) Cell signaling (5339)
pSMAD2 rabbit 1:1 000 (Immunoblot) Cell signaling (3108)
c-Met mouse 1:1 000 (Immunoblot) Cell signaling (3127)
p-Met rabbit 1:1 000 (Immunoblot) Cell signaling (3077)
ERK1/2 mouse 1:1 000 (Immunoblot) Cell signaling (4696)
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Table 4. Primary antibodies
Target Host species Dilution (application) Distributed by (Product#)
p-ERK1/2 rabbit 1:1 000 (Immunoblot) Cell signaling (9101)
IkB mouse 1:1 000 (Immunoblot) Cell signaling (4814)
CK19 mouse 1:500 (Immunohistochemistry) DSHB (TromaIII)
Radixin goat 1:200 (Immunohistochemistry) Santa Cruz (sc6408)
Mrp2 mouse 1:200 (Immunohistochemistry) Biozol (BLD-SIG-38785-500 )
Ly6G rat 1:400 (Immunohistochemistry) eBioscience (14-5931 )
CD3 rabbit 1:100 (Immunohistochemistry) Dako (A0452)
Ki67 rabbit 1:200 (Immunohistochemistry)
1:400 (Immunohistochemistry)
Pierce Thermo Scientific (MA5-14520 )
Cell Signaling  (12202)
F4/80 rat 1:150 (Immunohistochemistry) gift from Ruth Ganss (University of 
Western Australia, Perth, Australia)
CD44 rat 1:150 (Immunohistochemistry) eBioscience
panCK rabbit 1:200 (Immunohistochemistry) Dako 
panCK mouse 1:100 ( Immunohistochemistry) Dako
SMA mouse 1:400 (Immunohistochemistry) Dako
GFP rabbit 1:1 000 (Immunohistochemistry) abcam
Table 5. Secondary antibodies
Target Tag Dilution Distributed by
rabbit Alexa Flour® 488 1:200 Life Technologies (A-11034)
rat Alexa Flour® 594 1:200 Life Technologies (A-11007)
mouse Alexa Flour® 594 1:200 Life Technologies (A-11005)
mouse Horseradish peroxidase 1:5 000 ThermoScientific (31432)
rabbit Horseradish peroxidase 1:10 000 Dianova (111-035-144)
rat Horseradish peroxidase 1:15 000 Dianova (112-0,35-143)
mouse Biotin 1:200 Dako (E0433)
rabbit Biotin 1:600 Dako (E0432)
rat Biotin 1:200 Dako (E0468)
goat Biotin 1:200 Dako (E0466)
2.1.4 Cell lines
Table 6. Cell lines and respective culture media
Cell line Source of cells Culture medium Source Remarks
BMOL Murine liver Williams' E 
+2-5% FCS 
+ 2mM Glutamine
+ 15 ng/ml IGF-II
+ 10 ng/ml EGF
+ 5 µg/ml Insulin
Nina Tirnitz-Parker 
(Curtin University, 
Perth, Australia)
bipotential 
[109]
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2.1.5 Mice
Table 7. Mice
Mouse line Source Reference
129P2-Adam10tm2Psa/Ph Paul Saftig (University Kiel, Germany) [108]
B6.Tg(Alb1-cre)7Gsc/Cnrm Thomas Wunderlich (University Cologne, Germany) [110]
B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J Radislav Sedlacek (Institute of molecular genetics, Academy 
of Science of the Czech Republic, Prague, Czech Republic)
[111]
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2.2 Methods
2.2.1 Animal experimentation 
2.2.1.1 Housing of mice
All mice were housed in a specified pathogen free environment. Room temperature was 
stable at 22°C. Light conditions were according to a 12-hour day-night cycle. Mice were 
fed a standard laboratory chow (10 mm pellets; V1534-000, Ssniff, Soest, Germany) ad lib-
itum. Animals were treated humanely according to the criteria outlined by the German 
government. Experiments with CCl4 were approved by the according authority with the 
reference number V242-7224.121-3 (36-4/14).
2.2.1.2 Breeding of mice
Mice were at least 10 week old when used for breeding. For the duration of the breeding 
they received special breeding food (10 mm pellets; V1124-000, Ssniff, Soest, Germany) 
ad libitum. Pups were weened 3 weeks after birth. Until then, they received the same food 
as the parents. Breeding schematics for the different strains are depicted below:
Figure 2.1: Breeding schematic for Cre-activity reporter mice
Genotypes used in experiments are marked by a thick black frame. Mice expressing EYFP are highlighted in yellow. 
P: parental generation; F1: first generation (progeny of P)
Figure 2.2: Breeding schematic for conditional ADAM10 knockout in hepatocytes, cholangiocytes and liver 
progenitor cells
Genotypes used in experiments are marked by a thick black frame. Color schemes are equivalent to the ones used  
in bar charts for the respective genotype. 
P: parental generation; F1: first generation (progeny of P); F2: second generation (progeny of F1)
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2.2.1.3 Tail biopsy and genotyping
A 3-5 mm long biopsy was taken from the tail of 3-4 week old mice. To avoid cross-con-
tamination or inf lammation of the tail we used a hot-bead sterilizer in between animals. 
Tails were digested over night at 55°C and 1 000 rpm in 0.5 ml DNA-digestion buffer1. 
Insoluble materials were pelleted at maximum speed for 5 min and supernatant (SN) was 
transferred to a fresh tube. 170 µl of saturated NaCl were added and the sample was vigor-
ously shaken. Samples were centrifuged at maximum speed for 20 min to pellet proteins 
and SN was transferred to a new tube. DNA was precipitated by the addition of 1 ml 
EtOH and was pelleted at maximum speed for 5 min. Pelleted DNA was washed with 
70% EtOH and dried at room temperature. It was then resuspended in 100µl TE-Buffer 
and incubated at 50°C for 5-20 min to ensure complete dissolution. DNA was then ready-
to-use for genotyping PCRs.
For detailed information on genotyping primers please refer to Table 2.
Standard PCR mix:
2 µl DNA
3 µl 10x DreamTaqTM Buffer
3 µl dNTPs (2 mM)
1.5 µl 5' Primer (10 µM)
1.5 µl 3' Primer (10 µM)
0.2 µl   DreamTaqTM Polymerase
adjust to 30 µl with ddH2O
Cycle conditions:
Table 8. ADAM10-flox PCR conditions
Step Temperature Time Cycles
Initial Denaturation 95°C 2' 1
Denaturation 95°C 30''
30Annealing 55°C 30''
Elongation 72°C 30''
Final Elongation 72°C 10' 1
Storage 4°C ∞ 1
1 DNA-digestion buffer:  100 mM Tris-HCl pH 8.5, 5 mM EDTA, 200 mM NaCl, 0,2 % SDS, 0,3 mg/ml proteinase K (added fresh)
24
2 Material & Methods
Table 9. Cre PCR conditions
Step Temperature Time Cycles
Initial Denaturation 95°C 2' 1
Denaturation 95°C 30''
30Annealing 56°C 30''
Elongation 72°C 30''
Final Elongation 72°C 10' 1
Storage 4°C ∞ 1
Table 10. ROSA_STOP_EYFP PCR conditions
Step Temperature Time Cycles
Initial Denaturation 95°C 2' 1
Denaturation 95°C 30''
35Annealing 57°C 30''
Elongation 72°C 30''
Final Elongation 72°C 5' 1
Storage 4°C ∞ 1
2.2.1.4 Treatment with CCl4
8 to 10 week old mice received a total of 4 intraperitoneal injections of CCl4 in three day 
intervals. CCl4 was diluted 1:4 in sunf lower oil and mice received 793 µg CCl4 per g body 
weight. Mice were sacrificed 2 days, 15 days, or 30 days after the last injection.
2.2.1.5 Organ harvesting
Mice were killed by cervical dislocation. We took blood as described in 2.2.1.7. Following 
perfusion with ice-cold PBS2 liver, spleen, and kidney were harvested, weighed, and pro-
cessed according to the requirements of the destined use.
2 PBS: 136 mM NaCl, 2.68 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4, adjust to pH 7.4
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2.2.1.6 Bile duct plastination
Bile ducts were plastinated as described previously [7]. In brief, the common bile duct was 
isolated and f lushed with PBS2. Liquid Mercox II resin was mixed with catalyst (10% w/v, 
Ladd Industries, Burlington (VT, USA). The mixture was injected into the common bile 
duct which was then ligated. Livers were allowed to sit for approximately 10 min for resin 
to polymerize and were then resected from the abdominal cavity. Liver tissue surrounding 
the cast was digested with DNA-digestion buffer. Isolated casts were rinsed with H2O, 
dried, and imaged with a AZ100 microscope with a DS-Fi2 camera (Nikon, Düsseldorf, 
Germany).
2.2.1.7 Blood sampling and serological analysis
Blood was taken from the heart and transferred to microtubes with Lithium-Heparin (25 
I.U.  Heparin/  ml  blood).  Tubes  were  inverted  to  release  the  Heparin  into  the  blood 
sample. Samples were centrifuged at 2 000g for 10 min at RT. Plasma was transferred to 
fresh tubes and stored at -20°C or -80°C until further usage. Alanine transaminase and 
alkaline phosphatase serum levels were measured with Ref lotron® teststripes on a Ref lo-
tron® Plus System (Roche, Penzberg, Germany)
2.2.1.8 Hydroxyproline assay
Approximately 100 mg of liver tissue was homogenized with beads in a power homogen-
izer (Precellys, with an additional Cryolys cooling unit; distributed by Peqlab, Erlangen, 
Germany) in 900 µl ice cold H2O for 2 min at 6 000 rpm. Blended contents were trans-
ferred to a fresh tube and mixed with 50% Trichloracetic Acid to precipitate total protein. 
The mixture was vortexed and incubated for 20 min on ice. Afterwards the samples were 
centrifuged at 6 000 rpm for 10 min at 4°C. SN was discarded and the pellet was washed 
twice with ice-cold 100% EtOH. The pellets were then dried at RT, dissolved in 800 µl 
6M HCl, and incubated ON at  100°C. Samples  were centrifuged at  13 000 rpm and 
supernatant was withdrawn from the tubes using a syringe with a needle. Total volume 
within the syringe was documented for later calculations. The SN was filtered through a 
0.22 µm filter. 40 µl of the filtered liquid were mixed with 10 µl 10M NaOH and then 450 
µl of a freshly prepared Chloramine-T solution3 was added. Samples were incubated 25-30 
min at RT. Afterwards 500 µl of Ehrlich's Reagent4 were added and samples incubated 20 
3 Chloramine-T solution: 56 mM Chloramine-T, 10% n-Propanol, 704 mM Sodium Acetate Tri-hydrate, 192 mM Citric Acid, 160 mM Acetic 
  Acid, 680 mM NaOH, pH 6.5
4 Ehrlich's Reagent: 1M 4-(Dimethylamino)benz-aldehyd in 67% n-Propanol and 33% Perchloric Acid
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min at 65°C. Once samples had room temperature they were measured in triplicates using 
a Tecan microplate reader (Tecan, Männedorf, Switzerland) at 544 nm against a known 
standard.
Hydroxyproline content was calculated as follows:
µg /ml [measured ]×
SN µl
40
mg liversample = 
µg HYP
mg liver
2.2.1.9 Immunohistochemistry
Tissue was fixed ON at 4°C in 4% buffered Formaldehyde and subsequently stored in 1% 
Formaldehyde. Tissue samples were washed several times in ddH2O and then incubated 
ON in 50% EtOH. The next day samples were treated as follows:
60 min 70% EtOH
30 min 96% EtOH
60 min 96% EtOH
90 min 100% EtOH
120 min 100% EtOH
90 min Xylol 
90 min Xylol
30 min Paraffin
ON Paraffin
30 min Paraffin
Tissue samples were then stored in paraffin blocks and when needed cut into 4 µm thick 
sections for immunohistochemistry. Sections were deparaffinized, rehydrated, and subjec-
ted to heat-induced antigen retrieval in either citrate buffer5 or EDTA buffer6.
Sections were stained with hematoxylin-eosin, Sirius Red or Periodic-acid-Schiff using 
standard protocols.
Further sections were stained with primary antibodies (Table 4). Primary antibodies were 
either detected by biotyinlated secondary antibodies (Table 5), stained using a peroxidase 
DAB kit (Dako, Hamburg, Germany), and counterstained with Hematoxylin or detected 
by secondary f lourescence-coupled antibodies (Table 5) and counterstained with Hoechst 
33342.
5 Citrate buffer: 10 mM citric acid, 0.05% Tween20, adjust to pH 6
6 EDTA-Buffer:   1 mM EDTA, 0.05% Tween20, adjust to pH 8
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Sirius  Red+ and Ki67+ areas  were quantified by morphometric  evaluation with ImageJ 
software (IJ 1.46r, NIH, USA). 10 non-overlapping fields (20x magnification) per section 
were analysed for each mouse. 
2.2.1.10 Transmission electron microscopy
Tissue was fixed in 6% glutaraldehyde in 0.1 M phosphate buffer pH 7.2, postfixed with 
2% osmiums tetroxide and embedded in araldite. Sections were cut and stained with lead 
citrate and uranyl acetate. Images were taken on an EM900 Zeiss electron microscope 
(Zeiss, Oberkochen, Germany).
2.2.1.11 Cytokine Array on tissue samples
The cytokine array (Mouse Cytokine Array, Panel A #ARY006, R&D Systems, Wies-
baden-Nordenstadt,  Germany)  was performed on murine  liver  tissue  according to the 
manufacturer's instructions. 
2.2.1.12 ELISA
ELISAs detecting TNFα (#DY410, R&D Systems, Wiesbaden-Nordenstadt, Germany), 
IL-1RA (#DY480, R&D Systems, Wiesbaden-Nordenstadt, Germany), and CCL2 (#88-
7931-88, affymetrix eBioscience, Frankfurt a.M., Germany) were performed with murine 
liver tissue samples according to the manufacturer's instructions.
Multiplex assay analysis of sMet, HGF and amphiregulin levels in serum was executed 
with a Bio-Plex mouse array (Bio-Rad Laboratories, Prague, Czech Republic) using the 
Bio-Plex 200 System (Bio-Rad Laboratories, Prague, Czech Republic). Multiplex beads 
were produced by amine coupling reaction with primary antibodies from R&D (Min-
neapolis, USA) and validated in accordance with validation procedures and recommenda-
tions from Luminex.
2.2.1.13 Genomic DNA extraction from organs
Genomic DNA from organs was extracted as described in 2.2.1.3 for genomic DNA from 
tails. Approximately 10-20 mg organ was used per extraction.
2.2.1.14 Deletion PCR
Standard PCR mix was prepared as described in 2.2.1.3 with the primers listed in Table 2 
for ΔAdam10 and Hbbt1. Cycle conditions were as stated below:
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Table 11. ADAM10 deletion PCR conditions
Step Temperature Time Cycles
Initial Denaturation 95°C 5' 1
Denaturation 95°C 1'
30Annealing 61°C 1'
Elongation 72°C 3'
Final Elongation 72°C 10' 1
Storage 4°C ∞ 1
Table 12. Beta-globin PCR conditions
Step Temperature Time Cycles
Initial Denaturation 95°C 5' 1
Denaturation 95°C 30''
30Annealing 55°C 30''
Elongation 72°C 30''
Final Elongation 72°C 10' 1
Storage 4°C ∞ 1
2.2.1.15 mRNA Isolation
Total RNA was isolated from whole liver tissue using TRIzol (LifeTechnologies, Darm-
stadt, Germany) according to the manufacturer's instructions. RNA was always precipit-
ated ON at -20°C. 
2.2.1.16 cDNA generation through reverse transcription
mRNA was transcribed to cDNA with RevertAid™ Reverse Transcriptase (ThermoS-
cientific, Darmstadt, Germany). In short, equal amounts (≈ 1 µg) of mRNA were mixed 
with Oligo(dT)18 primer, reaction buffer, RiboLock™ RNase Inhibitor, dNTPs (10 mM), 
and RevertAid™ Reverse Transcriptase. Volume was adjusted with ddH2O to 20 µl. The 
mixture was incubated for 60 min at 42°C and the reaction was terminated by heating to 
70°C for 10 min. Reaction product was directly used for quantitative Real-Time PCR.
2.2.1.17 Quantitative Real-Time PCR
Samples for qRT-PCR were either analysed on a CFX Real-Timesystem (BIO-RAD, 
München, Germany) or a roche light cycler 480 II (Roche, Penzberg, Germany). Primers 
are listed in Table 3.
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2.2.2 Cell culture
2.2.2.1 Cell culture conditions
All cells were cultured in incubators at 37°C under a constant atmosphere of 5% CO2 and 
a relative humidity (RH) of 95%. The culture media were prepared and used as indicated 
in Table 6. All work was performed under aseptic conditions and all used materials were 
autoclaved or sterilized before-hand.
2.2.2.2 Passaging
Cells were expanded and upon conf luency passaged 1:5 – 1:10, depending on the cell line. 
Since all cell lines were adherent, they were detached using trypsin/EDTA. After the cells 
were visibly detached, they were resuspended in medium and spun down by centrifuga-
tion. The supernatant was then removed and the cells resuspended in fresh medium and 
distributed to new cell culture f lasks.
2.2.2.3 Freezing and thawing of cells
Cells in presence of DMSO can be stored for a longer time period at -80°C or -150 °C. 
The steps for freezing cells were the same as for passaging them, but instead of resuspend-
ing them in fresh medium they were resuspended in freezing medium (50% FCS, 40% 
cell type specific medium, 10% DMSO). They were slowly cooled down in a freezing 
container until they reached -80°C. Storage was continued at -80°C or frozen stocks were 
transferred to -150°C.
For thawing the cells, they were rapidly thawed at 37°C, then resuspended in their respect-
ive medium. Cells were spun down by centrifugation, supernatant was removed and cells 
were seeded in fresh medium.
2.2.2.4 Determination of cell count
To determine the concentration of cells in a solution, a small amount of the cells was 
counted in an improved neubauer hemocytometer. Number of cells in a volume of 100 nl 
was counted and multiplied by 104, to determine the amount of cells per ml.
2.2.2.5 TGFβ2, HGF, and Tnfsf12 (TWEAK) stimulation
BMOL cells were seeded in 5 ml regular medium at a density of 1x105 cells/ml in 6-cm 
dishes.  After  cells  were adherent they  were starved  (0.5% FCS,  1mM Glutamine,  7.5 
ng/ml IGF-II, 5 ng/ml EGF, 2.5 µg/ml Insulin) overnight. Following pretreatment with 
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3µM GI254023X or DMSO for 1 h cells  were stimulated with 1 ng/ml rhTGFβ2, 20 
ng/ml rmHGF, 50 ng/ml Tnfsf12 (TWEAK), or solvent for 15 min at 37°C.
2.2.2.6 Proliferation assay
BMOL cells were starved over several passages to 0.5% FCS and half the growth factors  
used in the growth medium (see Table 6). Cells were seeded in a 96-well plate with 2x104 
cells per well in 200 µl medium. At the time of the seeding cells were treated with the 
ADAM10 inhibitor GI254023X (3µM) or DMSO. Cells were incubated for 48h under 
normal cell culture conditions. Afterwards,  medium was changed to 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium  bromide  (MTT)-containing  medium  (0.5  mg/ml) 
and cells were incubated for another 4 hours. Medium was removed and formazan crystals 
were dissolved in equal amounts of isopropanol. Adsorption was measured at 595 nm.
2.2.2.7 Tube formation assay
A 24-well plate was coated with 300 µl slowly thawed Matrigel per well. Matrigel had a 
protein concentration of > 10 mg/ml and was left for at least 3h at 37°C, 5% CO2, and 
95% RH to solidify. 300 µl of a 2x105 cells/ml cell suspension plus the respective inhibitors 
were seeded on top of the Matrigel in each pre-coated well.  Cells  were incubated for 
approximately 24 h to form tubes.  Pictures of formed tubes were taken with a AZ100 
microscope with a DS-Fi2 camera (Nikon, Düsseldorf, Germany) and tube length and 
branching was evaluated with the ImageJ plugin 2D Skeleton.
2.2.3 Proteinbiochemistry
2.2.3.1 Protein lysate
Murine tissue samples were disrupted with beads in RIPA Buffer7 in a power homogenizer 
(Precellys, with an additional Cryolys cooling unit; distributed by Peqlab, Erlangen, Ger-
many) for 2 min at 6 000 rpm. Cultured cells were taken up directly in RIPA-Buffer. Lys-
ates were incubated for 15 min on ice. Afterwards cell debris was spun down and super-
natant was used for down-stream applications.
2.2.3.2 Determination of protein concentration
Protein concentration of lysates was determined via the Bradford test in technical duplic-
ates. Brief ly, 1 µl sample was added to 200 µl of Bradford solution (AppliChem, Darm-
7 RIPA-Buffer: 50 mM HEPES pH7.4, 150 mM NaCl, 1mM EDTA, 2 mM EGTA, 0,5% NP-40 , 50 mM NaF
add fresh: 1 mM PMSF, 1 mM NaV, 1.46 µM Pepstatin A, 1.54 µM Aprotinin, 2.1 µM Leupeptin
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stadt, Germany) and carefully mixed. Absorption was measured at 595 nm. For quantifica-
tion purposes calibration solutions, composed of known BSA concentrations in water (0.2 
– 1 µg/µl), were measured in parallel. 
2.2.3.3 Separation of proteins via SDS-PAGE
Proteins were separated according to their molecular weight by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. A 10% separ-
ating gel8 was prepared between two glass plates and after polymerization covered with a 
stacking gel9 in which a comb was inserted. After complete polymerization the gel was put 
in an electrophoresis chamber, immersed in electrophoresis buffer10, and the comb was 
removed. Protein samples were mixed with 5x loading buffer11 and then heated for 5 min 
at 95°C. The samples were then put for a short time on ice to cool them down. Prestained 
protein marker (PageRuler™ Prestained Protein Ladder, ThermoScientific, Darmstadt, 
Germany) and the samples were loaded in the prepared pockets. The gel was then run 
until the tracking dye reached the anodic end of the gel.
2.2.3.4 Immunoblot analysis of proteins
The electrophoretically separated proteins were transferred to a polyvinylidene f louride 
membrane or a nitrocellulose membrane via so-called electroblotting. The blotting appar-
atus was assembled as follows (from anode to cathode): sponge, 2 layers of 3MM Whatman 
paper, membrane, gel, 2 layers of 3MM Whatman paper, sponge. The assembly of the 
apparatus took place in transfer buffer12. It is important to put the composition together 
without air bubbles, because otherwise the transfer does not work properly. The blotting 
apparatus was then positioned in a blotting chamber, which was filled with transfer buffer. 
The transfer was either for 90 min at RT (100 V) or over night at 4°C (30 V). After a suc-
cessful transfer, the membrane was incubated for at least 1h in 5% BSA in PBS-T13 to 
block unspecific binding sites. Thereafter, the membrane was incubated with the primary 
anti-body14 also at least for one hour but preferably over night at 4°C. Following 3 wash 
steps with PBS-T, each 10 min, the membrane was treated for minimum 1 hour with the 
secondary HRP-coupled antibody15. Finally the membrane was washed 3 more times in 
8 Separating gel (10%): 10 % Acrylamide, 350 mM bis-Tris pH6.5, 0.1% SDS, 0.1% APS, 0.06% TEMED
9 Stacking gel: 4% Acrylamide, 350 mM bis-Tris pH6.5, 0.1% SDS, 0.1 % APS, 0.1% TEMED
10 Running buffer: 250 mM MOPS, 250 mM Tris, 5 mM EDTA, 0.5% SDS, 5 mM Sodium bisulfite
11 5x Laemmli buffer: 250 mM Tris-HCl pH 6.8, 10% SDS, 50% Glycerine, 5% β-Mercaptoethanol 0.5% Bromophenol blue
12 Transfer buffer: 25 mM Tris, 200 mM Glycine, 20% Methanol
13 PBS-T: 136 mM NaCl, 2.68 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4, adjust to pH 7.4 and add 0.05% Tween-20
14 primary antibody diluted in 5% BSA, 0.1 % Sodium azide in PBS-T, specific dilution given in Table 4
15 secondary antibody diluted in PBS-T, specific dilutions given in Table 5
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PBS-T and once in water. For developing, one volume reagent 1 was mixed with one 
volume reagent  2 from a chemoluminescence  kit  (ThermoScientific,  Darmstadt,  Ger-
many). The mixture was incubated for 1 min, then put on the membrane and incubated 
for 5 min. After the removal of superf luous liquid, blots were developed in an intelligent 
dark box (Fujifilm, Düsseldorf, Germany) with a LAS-1000 camera (Fujifilm, Düsseldorf, 
Germany). The particular exposure times were determined individually. 
2.2.3.5 Stripping of membranes
Membranes were covered with mild stripping buffer16 and incubated at RT for 5-10 min. 
This step was repeated with fresh buffer. Membranes were washed twice in PBS for at least 
10 min and afterwards washed twice in PBS-T for at least 5 min. Membranes were then 
ready for the blocking stage.
2.2.4 Statistics
Data are shown as mean  ± standard error of mean if not stated otherwise. Comparisons 
between two groups were performed by applying the student's t-test. If data did not have 
equal  variances  or  were  not  normally  distributed,  the  Mann-Whitney-U  test  was 
employed  instead.  All  analyses  were  conducted  using  SigmaPlot  12.0  Software  (Systat 
Software, Erkrath, Germany). A p-value <0.05 was considered statistically significant.
16 Mild stripping buffer: 200 mM Glycine, 3,47 mM SDS, 1% Tween-20, adjust pH to 2.2
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3 Results
ADAM 10 was shown to play a vital role in both organ development and tissue integrity in 
several organs. Yet, there are little data concerning ADAM10 in physiological and patholo-
gical situations of the liver. To assess the function of ADAM10 in the liver we conceived 
the following study.
3.1 Alfp-Cre is active in hepatoblasts, cholangiocytes, and hepatocytes
A complete knockout of ADAM10 is  embryonic lethal.  Therefore we used previously 
generated ADAM10f l/f l mice. ADAM10f l/f l mice have loxP sites f lanking exon 2 [108] (see 
Figure 1.10). Excision of exon 2 using a Cre-recombinase leads to a frame shift and con-
sequently to an immediate premature stop-codon, leading ultimately to an abrogation of 
ADAM10 expression. We crossed ADAM10f l/f l mice with mice carrying a Cre-recom-
binase under an albumin promoter with an additional α-fetoprotein enhancer [110]. Activ-
ity of the Cre-recombinase starts at embryonic day of gestation 10.5 and is limited to hep-
atoblasts, adult liver progenitor cells, cholangiocytes and hepatocytes [110].To confirm the 
location  of  Cre-induced  recombination  events  we  cross-bred  Alfp-Cre+ mice  with  a 
reporter  strain for  Cre  activity.  These reporter  mice  are  transgenic  for  a  loxP-f lanked 
STOP cassette followed by a sequence coding for enhanced yellow f luorescent protein 
(EYFP) which are inserted in the ROSA26 locus. ROSA26 is a locus known for con-
stitutive, ubiquitious expression in mice. When Cre-recombinase is present in these mice 
the STOP sequence is excised and enhanced yellow f luorescent protein is expressed in the 
Cre-positive tissues. These ROSA_STOP_EYFP mice can be used to monitor Cre-ex-
pression and for lineage-tracing (Figure 3.1 A).
We detected EYFP expression in ROSA_STOP_EYFP reporter mice that are heterozyg-
ous for Alfp-Cre by anti-GFP immunohistochemistry. Staining was observed in both 4 
week and 15 week old animals. Distribution of EYFP was in both age groups clearly lim-
ited to hepatocytes and cholangiocytes. Endothelial cells lining blood vessel are not stained 
(Figure 3.1 B, magnified area shows a bile duct surrounded by hepatic parenchyma and 
endothelial cells). Next to immunohistochemistry we also investigated EYFP expression 
by immunoblot analysis. In the livers of mice lacking Cre-recombinase no GFP signal was 
detectable whereas in the livers of mice with Cre-recombinase activity a signal was detect-
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able (Figure 3.1 C). Other tissues tested, like kidney and spleen, did neither show signals 
in  immunohistochemistry  nor  in  immunoblot  analysis  even if  animals  were  Alfp-Cre+ 
(data not shown). 
Figure 3.1: Alfp-Cre targets liver progenitor cells, cholangiocytes, and hepatocytes
A: Schematic of the ROSA_STOP_EYFP Cre reporter system. A floxed stop cassette followed by a sequence  
coding for EYFP is inserted in the constitutively active ROSA26 locus. Cre-recombinase leads to deletion of the  
stop  cassette  and  accordingly  to  expression  of  EYFP.  B: Alfp-Cre  targets  hepatocytes  and  cholangiocytes  as 
demonstrated by cross-breeding with ROSA_STOP_EYFP mice and subsequent anti-GFP (also detecting EYFP) 
immunohistochemistry of liver tissue sections. Scale bars indicate 50 µm. C: Immunoblotting of total liver extracts 
of ROSA_STOP_EYFP mice with or without Alfp-Cre using anti-GFP antibodies. β-actin serves as loading control. 
(Immunoblot courtesy of S. Wetzel.)
3.2 ADAM10ΔhepΔch mice show efficient recombination and deletion of 
ADAM10 in the liver
We bred mice that are homozygous for f loxed ADAM10. 50% carry the Alfp-Cre trans-
gene heterozygously, the other 50% are Cre-negative (see Figure 2.2). They are of a mixed 
129/C57BL6  background.  Mice  without  Alfp-Cre  will  be  from  now  on  termed 
ADAM10f l/f l and serve as littermate control. Mice that are tested positive for Alfp-Cre will 
be referred to as ADAM10Δhep/Δch.
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All further analysis was based on the premise that the bulk mass of the liver consists of the 
targeted hepatocytes and cholangiocytes. All tests were therefore performed on whole liver 
tissue unless stated otherwise.
ADAM10Δhep/Δch mice show an efficient recombination of the f loxed exon 2 of adam10 as 
proven by analysis of liver-derived genomic DNA (Figure 3.2 A). They furthermore dis-
play a significant reduction of ADAM10 on the transcriptional level at the age of 4 week. 
At the age of 15 week ADAM10 mRNA is still reduced compared to controls. However, 
the reduction is not statistically significant anymore at this age (Data shown in doctoral 
thesis of S. Wetzel). A reason for this can be the increased presence of cell types other than 
liver  progenitor  cells,  hepatocytes,  and  cholangiocytes  in  the  liver  due  to  the  later 
described occurring phenotype.
On the protein level we observed a reduction of both the pro-form and the mature form 
of ADAM10 in the KO-mice. The residual ADAM10 stems probably from non-targeted 
cells in the liver, like hepatic stellate cells (Figure 3.2 B).
Figure 3.2: Alfp-Cre expressing mice show an efficient recombination and deletion of ADAM10
A: Successful recombination of exon 2 of adam10 in ADAM10fl/fl mice expressing Cre under the Alb promoter and 
Afp enhancer elements.  B: ADAM10 protein expression is decreased in total liver extracts of ADAM10 fl/fl mice 
expressing Cre under the Alb promoter and Afp enhancer elements as shown by immunoblot. Asterisk marks  
unspecific band. Filled arrowhead marks pro-form of ADAM10. Blank arrowhead marks mature form of ADAM10. 
(Immunoblot courtesy of S. Wetzel.)
Data represent the mean ± standard error of the mean. (** - P<0.01)
ADAM10Δhep/Δch mice varied in the penetrance of the resulting phenotype. However, mice 
with  a  liver-specific  deletion  of  ADAM10  on  a  pure  (100%)  C57BL/6  background 
developed a similar phenotype but with a slower kinetic (personal communication with K. 
Chalupsky/ R. Sedlacek, Institute of molecular genetics, Academy of Science of the Czech 
Republic, Prague, Czech Republic). We concluded therefore, that the observed pheno-
type can be specifically traced back to a lack of ADAM10 in liver progenitor cells, hepato-
cytes, and cholangiocytes.
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For our analysis  we focused on 129/C57BL6 mice that  showed strong necrosis  and/or 
fibrosis. This was the case for approximately 30-50% of the ADAM10 f l/f l offspring that 
were also Alfp-Cre+.
3.3 Hepatic deficiency of ADAM10 leads to postnatal necrosis
Mice with a hepatic deficiency of ADAM10 showed macroscopic signs of liver damage at 
the age of 4 week. At the age of 15 week the white spots were no longer macroscopically 
visible. All ADAM10Δhep/Δch animals had elevated serum levels of alanine transaminases and 
alkaline phosphatases (data shown in the doctoral thesis of S. Wetzel). Both serve as mark-
ers for liver damage. We then analyzed hematoxylin and eosin (H&E) stained histological 
liver sections. In 4 week old mice we detected numerous foci of a pale pink staining that  
were located mainly in zone 2 of the liver between the portal triad and the central vein.  
The areas had a distinct sharp border and show most likely necrotic areas due to hepato-
cyte  death.  In  15  week  old  ADAM10Δhep/Δch mice  the  necrotic  regions  are  drastically 
reduced (Figure 3.3 A).
Figure 3.3: Mice deficient for ADAM10 in the liver develop spontaneous hepatocyte necrosis
A: Hematoxylin and Eosin (H&E) staining of histological sections reveals necrotic areas in zone 2 in the livers of 
ADAM10∆hep/∆ch mice.  The amount  of  necrotic  areas  is  reduced in  older  mice.  Necrotic  areas  are  marked by 
asterisk. Scale bars indicate 200 µm and in magnified areas 50 µm B: Livers of newborn ADAM10∆hep/∆ch mice show 
no abnormalities  compared  to  control  mice.  Scale  bars  represent  200 µm.  C: ADAM10∆hep/∆ch mice  develop 
hepatomegaly. (n=4-16)
Data represent the mean ± standard error of the mean. (*** - P<0.001)
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We wanted to examine if the necrotic spots were due to an embryonic developmental 
defect. To that end we sacrificed newborn mice and evaluated their livers in H&E stained 
histological sections for appearance of necrotic areas. Interestingly, the livers of newborn 
ADAM10Δhep/Δch mice showed no signs of necrosis or other alterations (Figure 3.3 B). We 
hence deduced that hepatocyte death is triggered by an event in postnatal liver develop-
ment.
Furthermore, we noticed that the liver weight (normalized to the body weight) of 4 week 
old ADAM10-deficient mice was significantly increased compared to control mice.  In 
older mice liver weight, though still elevated, approximates that of WT animals (Figure
3.3 C). It is probable that the increased liver weight is caused by a compensatory liver 
growth to adjust for the necrotic foci. 
3.4 Bile duct function but not formation is impaired in ADAM10ΔhepΔch mice
We hypothesized that, while not being caused by a prenatal developmental defect, hepato-
cyte death could be caused by impaired bile duct formation after birth. This seemed a 
likely explanation considering reports linking the ADAM10 substrate Notch2 to biliary 
development [6, 7, 112].
Figure 3.4: ADAM10Δhep/Δch mice show normal development of the biliary tree
Resin casts of the biliary tree show no distinct differences between WT and KO animals. Scale bars indicate 2000 
µm and in magnified areas 500 µm 
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In order to analyze the gross morphology of ADAM10Δhep/Δch mice we generated resin casts 
of the biliary tree of 4 week old mice. Resin casts of KO and WT animals look identical 
(Figure 3.4 A).
To investigate a possible effect of ADAM10 on biliary tube formation we set up an in vitro 
experiment with the bipotential BMOL progenitor cell line. BMOL cells are described to 
form luminal tubular structures, similar to bile ducts, when plated on Matrigel [113]. We 
used  inhibitors  to  block  the  activity  of  ADAM10  (GI254023X),  ADAM10  and  -17 
(GW208264X), and γ-secretases (DAPT) in BMOL cells.
Figure 3.5: ADAM10 does not impair Notch-dependent tube formation
A: Tube formation of BMOL cells on a matrigel layer is not diminished in the presence of the ADAM-Inhibitors 
GI251023X  and  GW208264X  but  by  the  γ-Secretase-Inhibitor  DAPT.  Scale  bar  represents  1000  µm  B: 
Quantification of A. All branches with at least one junction were counted and data were normalized to the control  
to account for variations between experiments. (n=5) 
Data represent the mean ± standard error of the mean. (* - P<0.05)
We observed no differences  in  tube formation in cells  when ADAM10 is  blocked by 
GI254023X. We see a slight but not significant reduction of both, total tube length and 
number of junctions, in cells treated with GW208264X. However, we can reproduce the 
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findings by Fiorotto et al [113] that inhibition of γ-secretase mediated cleavage by DAPT 
leads to shorter overall tube length and also to less junctions. Fiorotto et al correlated the 
reduction in tube length and junctions to Notch activation. Interestingly, we do not see an 
effect on tube-formation by blocking ADAM10 activity (Figure 3.5 A+B). This suggests 
that ADAM 10 is, in this model, not the α-sheddase responsible for Notch cleavage.
Figure 3.6: ADAM10Δhep/Δch mice have more ductular biliary structures but less functional bile canaliculi
A: Immunohistological staining of cytokeratin (CK) 19+ liver progenitor and biliary cells demonstrates a ductular 
reaction in the livers of ADAM10-deficient animals that increases over time. Scale bars indicate 100 µm and in  
magnified areas 50 µm. B+C: Immunohistological staining of Radixin and multidrug resistance-associated protein 2 
(Mrp2) in  liver tissue sections reveals reduced number of bile canaliculi  in  ADAM10-deficient livers.  Scale bars  
indicate 100 µm and in magnified areas 50 µm.
We wanted to examine biliary functionality in more detail in case of alterations on a cellu-
lar level. We stained histological liver sections for Cytokeratin (CK)-19+ cells. Cytokerat-
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in19 is a known marker for cells of the hepatobiliary tract. Although Cytokeratin19 stain-
ing did not differ in livers of newborn mice (data are shown in the doctoral thesis of S.  
Wetzel), we detected slightly more Cytokeratin19+ structures in 4 week old ADAM10-
deficient  mice.  The accumulation of  Cytokeratin19+ cells  was  further  amplified in  15 
week old ADAM10Δhep/Δch mice (Figure 3.6 A). This frustrane proliferation of biliary struc-
tures is termed ductular reaction. The underlying cause is proliferation of liver progenitor 
cells that, driven by Notch signaling, adopt a biliary fate. We examined the transcription 
levels of Notch receptors as well as those of downstream targets of the Notch pathway 
(data are shown in the doctoral thesis of S. Wetzel). Albeit we detected a slight decrease in 
Notch signaling we do not consider this critical for the observed phenotype.
Radixin is an ezrin-radixin-moesin protein in hepatocytes that is located to the bile can-
alicular membrane [114]. It is known to control the transport of apical bile transporters like 
the multidrug resistance-associated protein 2 (Mrp2) [115]. In the immunohistochemical 
stainings for Radixin we noted a striking difference between WT and KO in 15 week old 
mice. Whilst Radixin is evenly distributed in the livers of ADAM10 f l/f l animals, it is almost 
extinct in ADAM10Δhep/Δch mice (Figure 3.6 B). Mrp2 staining was as well reduced in 15 
week old ADAM10Δhep/Δch mice (Figure 3.6 C).
These results suggest that while the general architecture and formation of the biliary tree is 
unaffected by a liver-specific KO of ADAM10 the bile acid transport is impaired.
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3.5 Liver inflammation is not strongly upregulated despite massive hepatic 
parenchymal damage
Damage in liver tissue leads to a strong inf lammatory response. Levels of pro-inf lammat-
ory cytokines are increased and macrophages and granulocytes infiltrate the liver [17, 116]. 
Notwithstanding massive hepatic parenchymal damage, presence of F4/80+ macrophage 
was not increased in  ADAM10-deficient mice.  However  F4/80+ macrophage clustered 
around the arising biliary structures in 4 week old ADAM10∆hep/∆ch mice. This is not com-
pletely surprising since macrophages secrete growth factors for liver progenitor cells [26]. 
This distribution of macrophages was also found in 15 week old ADAM10∆hep/∆ch mice 
(Figure 3.13 A).
Figure 3.7: ADAM10∆hep/∆ch mice show enlarged spleen.
A: Macroscopic pictures of the liver and spleen. The spleens in animals with a hepatic deficiency of ADAM10 are  
increased. Linear dimension of the ruler is cm.  B: Quantification of the spleen weight compared to the body 
weight. (n=4-16)
Data represent the mean ± standard error of the mean. (** - P<0.01)
We observed mild infiltration of Ly6G+ neutrophil granulocytes to the necrotic foci of 
both age groups of ADAM10-deficient animals (Figure 3.8 A). The infiltrated neutro-
philic  granulocytes  removed necrotic  tissue  as  demonstrated  by  ultrastructural  analysis 
(Figure 3.8 B). ADAM10∆hep/∆ch mice had an increase in CD3+ T-lymphocytes that was 
mainly restricted to the immediate vicinity of the portal triad. We noticed almost no CD3+ 
cells in or around the necrotic areas (Figure 3.8 C).
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Figure 3.8: The inflammatory response to the hepatic damage in ADAM10∆hep/∆ch is limited
A: Immunohistochemical  staining  of  Ly6G  in  liver  tissue  discloses  infiltration  of  neutrophils  (marked  by 
arrowheads) to the necrotic areas. Scale bars indicate 50 µm B: Transmission electron micrographs of neutrophils 
removing necrotic liver tissue. Scale bars indicate 1000nm and in magnified areas 250 nm. hv: engulfed hepatocyte  
vacuole,  g:  engulfed  glycogen-filled  vacuole.  (courtesy  of  R.  Lüllmann-Rauch)  C: Liver  tissue  sections  of 
ADAM10∆hep/∆ch mice show an increase of CD3+ cells in the vicinity of biliary structures and few in the hepatic 
parencyhma. Arrowheads point to CD3+ cells. Scale bars represent 100 µm. 
Despite  a  comparatively  moderate  immune  response,  ADAM10∆hep/∆ch animals  showed 
spleenomegaly already at 4 week of age which was further increased at 15 week of age 
(Figure 3.7 A+B).
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Figure 3.9: Anti-inflammatory cytokines are upregulated in mice with liver-specific deficiency of ADAM10
A: A cytokine array was performed on the total liver extracts of 4 week old animals. A representative image for 
both  control  and  ADAM10  lacking  animals  is  shown.  All  arrays  are  quantified  in  the  bar  chart.  (n=2)  B: 
Quantification  of  ELISAs  for  tumor  necrosis  factor  α (TNFa),  chemokine  C-C  motif  ligand  2  (CCL2),  and 
Interleukin-1 receptor antagonist (IL-1RA) from total liver extract. (n=3-5)
Data represent the mean ± standard error of the mean. (*** - P<0.001)
We performed a cytokine array on tissue samples of 4 week old mice to test for alterations 
in cytokine and chemokine levels of KO mice compared to WT mice. 
44
3 Results
Surprisingly, only few proteins showed an alteration compared to the control samples (Fig-
ure 3.9 A). We decided to examine the proteins with the most distinct differences between 
WT  and  KO  animals  by  ELISA.  Despite  an  upregulation  in  the  cytokine  array, 
Chemokine C-C motif ligand 2 (CCL2) was not found to be upregulated in the ELISA. 
Neither was the pro-inf lammatory cytokine Tumor necrosis factor  α (TNFα).  But we 
confirmed a striking upregulation of interleukin-1 receptor antagonist (IL-1RA) (Figure
3.9 B). IL-1RA blocks interleukin-1 signaling and thus acts anti-inf lammatory [117]. IL-
1RA is also known to oppose senescence, possibly interfering with deactivation of hepatic 
stellate cells [118]. We reasoned that, whilst levels of pro-inf lammatory proteins stay con-
stant, upregulation of anti-inf lammatory proteins lead to the observed mild inf lammatory 
response, independent of the damage.
3.6 Hepatic regeneration processes are efficient in the repair of the lesions
When we stained for glycogen content with Periodic acid-Schiff we noticed that necrotic 
spots are surrounded by hepatocytes that have a lower glyogen content than hepatocytes in 
non-damaged areas (Figure 3.10 A).
Figure  3.10:  Glycogen content of  hepatocytes in the livers  of  ADAM10∆hep/∆ch animals is  reduced around 
necrotic areas.
New healthy hepatocytes arise around the necrotic areas. Due to their low glycogen content they appear  lighter  
than the surrounding older hepatocytes. Scale bars indicate 200µm and in the magnified areas 50 µm. 
Since the latter hepatocytes are stained strongly for glycogen and since animals were not 
starved, we concluded that those are newly formed hepatocytes indicating regeneration. 
45
3 Results
The observation that the lighter stained cells appear only around older necrotic areas (par-
tially dissolved cells, 15 week panel) and not around fresher necrotic areas (cells still have 
hepatocytic morphology, 4 week panel) suggests that the lighter stained cells are not newly 
necrotic cells.
Figure 3.11: Increased proliferation in ADAM10∆hep/∆ch animals
A: Proliferative areas in the liver as assessed by Ki67 staining. Scale bars represent 200 µm and in the magnified  
areas 50µm.  B: Quantification of B attests the increase of proliferation in the livers of ADAM10∆hep/∆ch animals. 
(n=3-15) 
Data represent the mean ± standard error of the mean. (*** - P<0.001)
Due to the earlier observation that necrotic lesions are reduced in 15 week old KO mice 
compared to 4 week old KO mice we investigated hepatic regeneration processes. We thus 
stained liver  sections with Ki67 antibody to assess  proliferative activity.  In 4 week old 
ADAM10∆hep/∆ch mice the amount of proliferating cells was almost doubled compared to 
controls. The same is the case for 15 week old animals, although total area covered by 
Ki67+ cells  was  lower.  We  reasoned  that  total  numbers  are  reduced  in  older  animals 
because less proliferation is needed to repair the few remaining necrotic lesions (Figure
3.11 A+B). 
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3.7 Loss of ADAM10 leads to activation and proliferation of the liver 
progenitor cell compartment
Interestingly, we found not only hepatocytes that were positive for Ki67 but also small cells 
with little cytoplasm. Their morphology led us to hypothesize that they are liver progen-
itor cells. To investigate this, we stained liver tissue sections for pan-cytokeratin (panCK), 
a marker found in both biliary epithelial cells and liver progenitor cells, and Ki67 (Figure
3.12).
Figure 3.12: Detection of proliferating liver progenitor cells in 15 week  ADAM10∆hep/∆ch mice.
Immunofluorescent  co-staining  of  pan-cytokeratin  (panCK)  and  the  proliferation  marker  Ki67  in  liver  tissue. 
Asterisk mark unspecific panCK staining of necrotic hepatocytes. Arrows indicate panCK+ Ki67+ liver progenitor 
cells. Scale bars indicate 100 µm. Magnified areas are marked by dashed squares.
In ADAM10f l/f l mice we detected only pan-cytokeratin+ biliary epithelial cells in the portal 
triad. Whereas in animals deficient for ADAM10 in the liver we saw the earlier described 
ductular reaction (see page  38) as well as single pan-cytokeratin+ liver progenitor cells in 
the parenchyma. And indeed, we observed pan-cytokeratin+ Ki67+ liver progenitor cells in 
47
3 Results
15 week old animals supporting our earlier notion of proliferating liver progenitor cells in 
the older animals.
Figure 3.13: Liver progenitor cells in the vicinity of ductular reactions
Ductular reaction and accumulation of  liver progenitor cells  as marked by pan-cytokeratin (panCK) and CD44 
staining  of  liver  tissue  sections  of  ADAM10∆hep/∆ch mice.  Images  from  4-week  old  wild  type  animals  are 
representative for  both age groups. Asterisk mark unspecific  panCK staining of  necrotic  hepatocytes.  Arrows 
indicate potentially tumorigenic panCK+ CD44+ liver progenitor cells. Scale bars indicate 50 µm. Magnified areas are 
marked by dashed squares.(courtesy of J. Köhn)
To  examine  the  pan-cytokeratin+ cells  more  thoroughly,  we  additionally  investigated 
CD44 expression. CD44 is a receptor for hyaluronic acid but can also bind other ligands, 
such as osteopontin. CD44 is proposed to regulate cell-cell and cell-matrix interactions 
and thereby inf luences cell adhesion and migration [119]. CD44 signaling can be regulated 
through ADAM10-mediated ectodomain shedding [58]. Due to its role in migration and 
tumor progression, CD44 has been discussed as a liver cancer stem cell marker [29]. In the 
thioacetamide model of chronic liver injury CD44 is initially mainly found on macro-
phages but as injury progresses CD44 expression is also found in panCK+ progenitor cells 
(personal  communication with J.  Köhn/  N. Tirnitz-Parker,  School of  Biomedical  Sci-
ences, Curtin University, Perth, Australia). We observe in our model a similar distribution 
of CD44. In younger animals CD44 staining is restricted to immunocytes in necrotic areas 
or  surrounding ductular  areas,  whereas  in  15 week old  mice  CD44 co-localized with 
panCK (Figure 3.13).
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Figure 3.14: Ductular reaction and proliferation of liver progenitor cells
Ductular reaction and accumulation of liver progenitor cells in ADAM10∆hep/∆ch mice as marked by pan-cytokeratin 
and F4/80 macrophage staining of liver tissue sections  Scale bars represent 50 µm. (courtesy of J. Köhn) 
In co-stainings for pan-cytokeratin and F4/80 we noted a clustering of macrophages in 
ADAM10∆hep/∆ch mice compared to controls, where macrophages were distributed more 
equally. The clustered macrophages were mainly in close proximity to pan-cytokeratin+ 
cells (Figure 3.14). At present we can not state whether the F4/80 cells consist of Kupffer  
cell or also of infiltrated macrophages. Macrophages are described to be the source of the 
liver progenitor cell mitogen tumor necrosis factor-like weak inducer of apoptosis (Tnfs-
f12, also known as TWEAK) that binds to its receptor Tnfrsf12a (also known as Fn14) 
expressed by liver progenitor cells and thereby driving progenitor cell proliferation [26].
Thus we measured mRNA levels of Tnfsf12 and Tnfrsf12a in whole liver extracts. While 
we did not observe an upregulation of Tnfsf12, we discovered significantly increased levels 
of Tnfrsf12a in ADAM10∆hep/∆ch animals (Figure 3.15 A). This increase can be due to an 
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upregulation of expression, to an increase in numbers of cells expressing Tnfrsf12a, or to a 
combination of both.
These observations are in accordance with previous findings showing that release, but not 
expression, of Tnfsf12 is altered whereas Tnfrsf12a expression on liver progenitor cells is 
upregulated [26]. This supports the notion that these mice show an increased proliferation 
of liver progenitor cells.
Figure 3.15: Proliferation of Liver progenitor cells is elevated in the absence of ADAM10 activity
A: Expression  levels  for  Tnfsf12 and  Tnfrsf12a show  an  increased  expression  of  the  receptor  Tnfrsf12a in 
ADAM10∆hep/∆ch mice. (n=4-5)  B: BMOL cells with inhibited ADAM10 activity show a stronger proliferation after 
48h (n=3) 
Data represent the mean ± standard error of the mean. (* - P<0.05; *** - P<0.001)
In line with these findings we detected increased proliferation of the progenitor cell line 
BMOL when ADAM10 activity is blocked by the inhibitor GI254023X (Figure 3.15 B).
3.8 ADAM10 regulated signaling in liver progenitor cells
We decided to explore signaling pathways that contribute to liver progenitor cell activation 
and proliferation and that might be regulated by ADAM10. As described above, we found 
Tnfrsf12a upregulated,  indicating increased signaling in the Tnfsf12-Tnfrf12a pathway. 
Additionally,  we  found  increased  levels  of  hepatocyte  growth  factor  in  the  sera  of 
ADAM10∆hep/∆ch mice whereas levels of its receptor c-Met were not altered (Figure 3.16 A). 
We also detected upregulation of amphiregulin in the serum of ADAM10ΔhepΔch mice that 
was, however, not significant. We thus stimulated the liver progenitor cell line BMOL 
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with recombinant Tnfsf12 and hepatocyte growth factor while downregulating ADAM10 
activity  either  by  adding  the  inhibitor  GI254023X  or  by  downregulating  ADAM10 
expression through siRNA. We then analyzed phosphorylation of the hepatocyte growth 
factor  receptor  c-Met  and  the  downstream  target  extracellular-signal-regulated  kinase 
(ERK) by immunobloting. We additionally examined IκB by immunoblot, since stimula-
tion with Tnfsf12 leads to phosphorylation and consequently degradation of IκB, releasing 
NF-κB to the nucleus [120]. We detected phosphorylation of c-Met after stimulation with 
hepatocyte growth factor and that this was increased after downregulation of ADAM10 
activity  either  by  GI254023X-mediated  inhibition  or  siRNA.  Accordingly,  we  noted 
phosphorylation  of   extracellular-signal-regulated  kinase  that  was  also  increased  after 
downregulation of ADAM10 activity (Figure 3.16 B, siRNA experiments shown in doc-
toral thesis of S. Wetzel). We observed no alteration in post-stimulatory IκB levels inde-
pendent of ADAM10 activity (Figure 3.16 B, siRNA experiments shown in doctoral thesis 
of S. Wetzel).
Figure 3.16: Enhanced c-Met signaling in liver progenitor cells in the absence of ADAM10 activity
A: Multiplex ELISA shows increased levels of the liver progenitor cell mitogens amphiregulin and hepatocyte growth 
factor (HGF) in the serum of ADAM10∆hep/∆ch  animals. (n=3-15, courtesy of K. Chalupsky). B: HGF-induced  c-Met 
signaling   but   not  TWEAK-induced  Fn14  signaling  is  increased  in  the  presence  of  the  ADAM10  inhibitor 
GI254023X. Shown is  one out of three independent experiments. (Blot courtesy of B. Wöhner)
Data represent the mean ± standard error of the mean. (** - P<0.01)
TGFβ ligands are known to be upregulated in chronic liver injuries and to contribute to a 
preference of liver progenitor cell-driven regeneration over hepatocyte-driven regenera-
tion [121]. We thus investigated expression levels of  Tgfb1 and  Tgfb2. Whilst  Tgfb1 was 
51
3 Results
only mildly upregulated in livers of 15 week old KO mice, we found Tgfb2 to be strongly 
elevated in these animals (Figure 3.17 A). We analyzed additionally TGFβ2 signaling in 
liver progenitor cells in an in vitro setting. Our experiments show that phosphorylation of 
Smad2,  downstream  of  TGFβ2,  is  enhanced  in  BMOL  cells  in  the  presence  of  the 
ADAM10 inhibitor  GI254023X while  total  levels  of  TGFβ receptors  I  and II  are  not 
changed (Figure 3.17 B). Future analyses will show whether the increased phosphorylation 
of SMAD2 also results in altered expression levels of genes downstream of TGFβ signaling.
Figure 3.17: Increased TGFβ2 signaling in the absence of ADAM10 activity
A: Elevated expression levels of  Tgfb1 and  Tgfb2 in mice lacking ADAM10 in the liver. (n=4-5).  B: Inhibition of 
ADAM10 activity increases TGF 2 signaling in liver progenitor cells. BMOL cells were stimulated with 1 ng/mlβ  
rhTGF 2 for 15 min at 37°C, subsequently lysed and analysed by immunoblotting using the indicated antibodies.β  
Shown is one representative out of three independent experiments. 
Data represent the mean ± standard error of the mean. (** - P<0.01)
3.9 Animals with hepatic deletion of ADAM10 show progressing liver fibrosis
Liver  progenitor  cell  activation  and  proliferation  after  chronic  liver  injury  has  been 
demonstrated to activate hepatic stellate cells and lead to the development of liver fibrosis 
[122].
Both age groups of ADAM10∆hep/∆ch mice show strong activation of hepatic stellate cells as 
detected by immunohistological staining of  α  smooth muscle actin (αSMA). In control 
animals only αSMA expressing myofibroblasts were detected (Figure 3.18 A). This finding 
can be further substantiated by analysis of expression levels of αSMA that show a signific-
ant increase in 15 week old ADAM10∆hep/∆ch animals compared to controls (Figure 3.18 B). 
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In electronmicrographs of 15 week old ADAM10f l/f l animals we found quiescent hepatic 
stellate cells that feature huge intracellular lipid droplets. We found, in accordance with 
our previous findings, activated hepatic stellate cells in 15 week old ADAM10∆hep/∆ch anim-
als that have hardly any lipid vacuoles and are surrounded by deposited collagen fibers 
(Figure 3.18 C).
Figure 3.18: Activation of hepatic stellate cells in ADAM10∆hep/∆ch mice
A: Histological staining of  smooth muscle actin in liver sections demonstrates activation of hepatic stellate cells.α  
Scale bars represent 200 µm. B: Expression levels of the   smooth muscle actin gene (α Acta2) is increased in animals 
that are deficient for ADAM10 in the liver. (n=4-9) C: Electronmicrograph of hepatic stellate cells in control animals 
and  animals  lacking  ADAM10  in  the  liver.  Open  arrow  indicates  quiescent  hepatic  stellate  cell  with  many  
intracellular  lipid  vesicles.  Filled  arrow points  to  activated  hepatic  stellate  cell.  S:  sinusoid.  C:  collagen  fibers.  
(courtesy of R. Lüllmann-Rauch) D: Expression levels of the fibrosis-associated genes for the chemokine-receptors 
Cxcr4 and Cxcr7 and the downstream transcription factor Id1. (n=4-5).
Data represent the mean ± standard error of the mean. (* - P<0.05; ** - P<0.01; *** - P<0.001)
It has recently been described, that liver sinusoidal endothelial cell in the hepatic vascular 
niche  deploy  angiocrine  factors  in  response  to  liver  injury  to  stimulate  regeneration. 
Depending  on  the  differential  recruitment  of  angiocrine  factors  this  supports  either 
regeneration or fibrosis. In the vascular niche the CXCR7-Id1 pathway stimulates a pro-
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regenerative response, whereas the FGFR1-CXCR4 pathway promotes fibrosis [123]. We 
therefore analyzed expression levels of both chemokine receptors as well  as that of the 
downstream transcription factor Id1 in whole liver tissue. We discovered that on the one 
hand expression levels of  Cxcr4 are upregulated in both 4 week and 15 week KO mice. 
Cxcr7 expression levels on the other hand are only elevated in 15 week old mice. Expres-
sion of Id1 is not elevated compared to healthy controls (Figure 3.18 D) suggesting a pro-
fibrotic response, which we observed in our animals. 
Figure 3.19: Mice deficient for ADAM10 in the liver show upregulation of fibrosis-associated genes.
A: Expression  of  fibrosis-related  matrix  metalloproteases  2  (Mmp2)  and  13  (Mmp13)  as  well  as  secreted 
phosphoprotein 1 (Spp1)  assessed by qRT-PCR. (n=4-9).  B: Upregulated expression level of tissue inhibitor of 
metalloprotease (Timp1) in livers of ADAM10∆hep/∆ch mice. (n=4-5).
Data represent the mean ± standard error of the mean. (* P<0.05; ** P<0.01)
In an extended study of other fibrosis-associated genes we identified also secreted phosphop-
rotein 1 (spp1, also known as osteopontin), matrix metalloprotease 2 (Mmp2) and 13 (Mmp13), 
and  tissue  inhibitor  of  metalloprotease  1  (Timp1) to  be  upregulated  in  15  week  old 
ADAM10∆hep/∆ch mice.  Timp1 was  already  significantly  elevated  in  4  week  old 
ADAM10∆hep/∆ch mice (Figure 3.19 A+B). This was of special interest to us since TIMP1 
does not only inhibit MMP activity but has also been described to inhibit ADAM10 [124].
Strikingly though, we already observed mild but significant increased amounts of collagen 
compared to control mice in 4 week old mice. As can be clearly seen in the tissue stain-
ings, collagen deposits were mainly limited to the vicinity of vessels in this age group. 
However in 15 week old ADAM10∆hep/∆ch mice collagen staining by sirius red increased 
greatly in comparison to both 15 week old ADAM10f l/f l mice. Collagen staining was also 
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elevated in 15 week old ADAM10∆hep/∆ch mice compared to 4 week old ADAM10∆hep/∆ch 
mice (Figure 3.20 A+B). Observed fibrotic patterns can be classified as a mixture between 
portal fibrosis and pericellular fibrosis (compare  Figure 1.4) Analyses of hydroxyproline 
content and expression levels of Collagen1A1 consistently support the previous findings of 
massive fibrosis in 15 week old  ADAM10∆hep/∆ch mice (Figure 3.20 C).
Figure 3.20: Mice deficient for ADAM10 in the liver present progressing liver fibrosis.
A: Histological liver sections stained for collagen deposition with Sirius Red. Scale bars represent 200 µm. B : 
Quantification of Sirius Red—positive areas proves significant collagen deposition in the livers of ADAM10∆hep/∆ch 
animals. (n=4-16) C: Quantification of hydroxyproline content (n=3-9) and analysis of Collagen1a1 expression (n=4-
9) from total liver extracts. Both confirming elevated levels of collagen in mice lacking ADAM10 in the liver.
Data represent the mean ± standard error of the mean. (** P<0.01; *** P<0.001)
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3.10 Induced liver damage via CCl4 does not lead to sustained liver fibrosis in 
ADAM10ΔhepΔch animals
We observed that ADAM10 apparently plays a role in liver progenitor cell-driven regener-
ation. However, we wanted to investigate if ADAM10 is involved in hepatocyte-driven 
regeneration as well. We thus employed a CCl4-induced damage model known to provoke 
repair through hepatocyte proliferation [125]. The experimental setup is depicted in Fig-
ure 3.21 A.
Figure 3.21: Recovery from CCl4-induced damage is not altered in ADAM10ΔhepΔch mice
A: Schematic of CCl4 treatment and subsequent liver analyses. Animals were injected 4 times with CCl4 in three 
day intervals. 2, 15, and 30 days after the last injection animals were sacrificed and their livers examined B: Liver 
weight, compared to body weight, is elevated 2 days (I2) after the last CCl 4-injection but returns to normal if more 
time passed between the injection and analysis (I15, I30). (n=5-11) C: Alanine transaminase (ALT) levels are elevated 
2 days (I2) after the last CCl4-injection but return to normal if more time passed between the injection and analysis 
(I15, I30). (n=6-11)
Data represent the mean ± standard error of the mean.
We detected an increase in alanine transaminase levels and relative liver weight two days 
after  the  last  injection,  indicating  liver  damage.  Yet,  the  injury  seems  to  be  resolved 
between 2 days after the last injection and 15 days after the last injection, since values for  
both alanine transaminases and relative liver weight return to normal during that time 
span. We did not observe differences between control animals and ADAM10∆hep/∆ch animals 
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at any time point of investigation. Neither amount of damage nor time needed for resolu-
tion  differs  between  the  two  groups  (Figure  3.21 B+C).  We  hence  concluded,  that 
ADAM10 does not play a role in hepatocyte-driven regeneration in this model, but fur-
ther analysis is needed to corroborate this hypothesis.
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4 Discussion
The liver is a very resilient organ and can regenerate from severe acute injuries, including 
loss of over 70% of its mass. However, chronic injuries through virus infections, alcoholic 
liver disease or non-alcoholic fatty liver disease cause the liver to become fibrotic and, if  
injury continues, cirrhotic (see chapter 1.1.4). Although regeneration from fibrosis is pos-
sible, the only available therapy that helps patients suffering from cirrhosis in the long-
term is organ transplantation. But organ donors are sparse and transplantation, as a surgical 
intervention, always carries a risk. Therefore, it is crucial to get a better understanding of 
the  molecular  mechanisms  orchestrating  regeneration,  fibrosis  and  liver  homeostasis. 
ADAM10 was reported to be an essential regulator of homeostasis in the skin, intestine, 
and in B cells [92-94]. We were thus interested if ADAM10 is also involved in liver tissue 
homeostasis.
4.1 ADAM10 in bile duct development and hepatocyte necrosis
One of the most prominent targets of ADAM10 is Notch which, after ligand binding, 
undergoes ADAM10-mediated shedding and leads to altered gene expression. Processing 
of Notch by ADAM10 has not only been implicated in tissue homeostasis  but also in 
embryonic  development  [93,  108].  Notch  receptors,  amongst  them foremost  Notch2, 
have been shown to be fundamental for biliary development and correct formation of the 
three-dimensional  architecture of the biliary tree,  as  well  as  for  biliary specification of 
adult progenitor cells  [6, 7]. Very interestingly though, mice deficient for ADAM10 in 
hepatoblast after e9.5 and consequently in hepatocytes and cholangiocytes did not show a 
developmental defect in their biliary structure. Adult  ADAM10∆hep/∆ch mice also exhibit 
functional  cholangiocyte differentiation after injury.  These findings suggest,  that either 
ADAM10 is not processing Notch during biliary-development or that loss of ADAM10 is 
compensated  for  by  another  protease  (see  Figure  4.1).  Although  the  closely  related 
ADAM17 shares many substrates with ADAM10, it was shown recently, that ADAM17 
does not play a role in shedding of Notch2  [56]. We additionally tested in cell-culture 
based experiments whether tube formation of the liver progenitor cell  line BMOL on 
matrigel is abrogated in the presence of ADAM- and γ-secretase inhibitors. In accordance 
with our  in vivo data inhibition of ADAM10 activity by GI254023X did not lead to an 
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altered tube formation. Inhibition with GW208264X, reported to block ADAM10 and 17 
activity, did lead to a slight but not significant decrease in either tube formation or branch-
ing. However, inhibiting γ-secretase cleavage by DAPT caused a significant reduction in 
tube length and junctions. These results indicate, that another protease is responsible for 
Notch2  processing  in  the  context  of  biliary  development.  Membrane-tethered  matrix 
metalloproteinase (MT1-MMP) was shown to cleave Notch in melanoma cells and can 
reconstitute  Notch  processing  in  ADAM10/17  double  knock-out  murine  embryonal 
fibroblasts [126].
 These results should be confirmed with studies using siRNA or shRNA. It might also be 
interesting  to  use  broad-spectrum metalloprotease  inhibitors  like  marimastat  to  see  if 
blocking all metalloproteases leads to a similar decrease in branching and tube length as γ-
secretase inhibition.
Figure 4.1: Biliary specification of progenitor cells depends on Notch-signaling
Schematic of the Notch-dependent differentiation process of hepatoblasts during development or liver progenitor  
cells after chronic damage. After binding to Jagged-1 of surrounding mesenchymal cells Notch undergoes shedding  
and  regulated intramembrane  proteolysis  and the  intracellular  domain  translocates  to  the nucleus.  There the  
intracellular domain initiates gene transcription inducing differentiation towards cholangiocytes. We show in our 
study  that  ADAM10  is  not  the  protease  responsible  for  the  α-secretase  cleavage  of  Notch  during  biliary 
differentiation.
Bile acids are produced in hepatocytes and then exported via bile acid transporters to the 
bile canaliculi. We observed a loss of radixin in ADAM10∆hep/∆ch mice. Radixin is respons-
ible for directing the bile acid transporter multidrug resistence-associated protein 2 (also 
ATP-binding cassette sub-family C member 2, Abcc2) to the bile canalicular membrane. 
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As a consequence multidrug resistance-associated protein2 staining on the cell surface was 
also reduced in these mice. Additionally we observed a downregulation on mRNA level 
for both rdx and abcc2 (data shown in doctoral thesis of S. Wetzel). There are no reports 
linking ADAM10 or Notch to bile transporters. It has been reported that impaired bile 
export from hepatocytes leads to hepatocyte necrosis mediated via reactive oxygen forma-
tion of attracted neutrophils [127]. Areas of hepatocyte necrosis caused by biliary accumu-
lation are referred to as bile infarcts. In accordance with these observations we also detect 
neutrophils in the necrotic areas of ADAM10∆hep/∆ch mice. We will therefore measure react-
ive oxygen species in tissue of these mice to investigate if this is the cause of the observed 
cell death. Considering though, that Radixin-deficient mice only show a mild phenotype 
it is possible that other bile acid transporters are impaired as well [114]. Another reason for 
the observed bile infarcts might be an altered bile metabolism. To investigate this further, 
we will not only analyze expression of several bile acid transporters but also examine total 
bile acid composition in ADAM10∆hep/∆ch mice. 
Further  experiments  are  also  needed to  confirm experimentally  that  the  detected cell 
death is indeed necrotic and not apoptotic. 
Despite the massive necrosis, infiltration of immune cells and inf lammation is rather low 
in the ADAM10-KO mice. We see a few neutrophil granulocytes in the bile infarcts and 
CD3+ T-cells  in the vicinity of  the portal  triad.  F4/80+ macrophage presence  was not 
increased in ADAM10∆hep/∆ch mice but they were localized in clusters compared to an uni-
form distribution in control animals (see Figure 3.14). These observations correspond to 
the  cytokine  profile  that  shows  no  increase  for  pro-inf lammatory  cytokines  or 
chemokines.  Instead  the  anti-inf lammatory  interleukin-1  receptor  antagonist  is  highly 
upregulated. Interleukin-1 receptor antagonist is known for balancing IL-1 signaling and 
exerting an anti-inf lammatory function [117]. Interleukin-1 receptor antagonist has been 
shown to reduce inf lammation and accelerate liver regeneration through acceleration of 
hepatocyte proliferation after partial hepatectomy  [128]. It is possible that interleukin-1 
receptor antagonist also exerts this role in favor of regeneration after a different type of 
liver injury. Interleukin-1 receptor antagonist can also act anti-senescent, possibly interfer-
ing with deactivation of hepatic stellate cells or even with deactivation of liver progenitor 
cells [118].
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Additionally, absence of ADAM10 can contribute to a less inf lammatory profile.  Sub-
strates of ADAM10 including pro-inf lammatory cytokines like tumor necrosis factor  α 
and interleukin-12 might not be released by ectodomain shedding. No elevation of tumor 
necrosis factor α levels was detectable in the respective ELISA for ADAM10ΔhepΔch  animals 
despite the obvious injury. It has recently been shown that deletion of ADAM10 in myel-
oid cells results in a less inf lammatory and more fibrotic phenotype in artherosclerosis 
[129].
4.2 Proliferation of liver progenitor cells
After liver injury two modes of regeneration are known that depend on the type of dam-
age. Proliferation of hepatocytes usually occurs after acute damage whereas if damage per-
sists liver progenitor cells get activated, proliferate, and differentiate (see chapter 1.1.2).
Several observations in the ADAM10∆hep/∆ch mice lead us to hypothesize that regeneration 
in these mice is liver progenitor cell-driven. First, though necrosis is strongly decreased in 
15 week old animals it is still present, arguing for a rather chronic damage. Second, we see  
in Ki67 stainings that mostly cells with an oval nucleus and little cytoplasm are proliferat-
ing instead of the bigger hepatocytes. Third, we detect a ductular reaction in cytokeratin 
19 stainings that is known to accompany liver progenitor cell-driven regeneration. Last, 
we observe cells that are double-positive for the progenitor marker pan-cytokeratin and 
the  proliferation  marker  Ki67.  We  therefore  investigated  macrophage  localization  and 
expression of  Tnfsf12 (coding for TWEAK) and  Tnfrsf12a (coding for Fn14) known to 
drive liver progenitor cell proliferation  [26]. While we see a clustering of macrophages 
especially around pan-cytokeratin+ cells, expression of Tnfsf12 is not increased. This is in 
accordance with previous reports showing constitutive  Tnfsf12 expression  [26]. But we 
found  Tnsfrsf12a to be increased which can either indicate increased expression on the 
same amount of cells or more cells expressing the receptor. 
Liver  progenitor  cell  proliferation increased although damage decreased over time. We 
hypothesize hence that ADAM10 is involved in termination of liver progenitor cell prolif-
eration in mice with a liver-specific deficiency of ADAM10. It could be that ADAM10 is 
needed  for  shedding  of  Tnfrsf12a  to  abrogate  signaling.  Although  Tnfrsf12a  is  not 
described as a substrate for proteolysis other members of the tumor necrosis factor receptor 
superfamily are known to undergo ADAM-mediated shedding [130]. 
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Yet, also other substrates of ADAM10 could be responsible for driving liver progenitor cell 
proliferation. Hepatocyte growth factor and its receptor c-met are important in hepato-
blast proliferation, and this also holds true for adult progenitor cells [25, 131]. C-met is a 
substrate of ADAM10 and loss of ADAM10 may cause prolonged and intensified c-met 
signaling [124]. We detected increased levels of hepatocyte growth factor in serum of mice 
with a liver-deficiency of ADAM10 arguing for an activation of the hepatocyte growth 
factor  signaling  pathway.  In  in  vitro experiments  we  showed  that  c-Met  signaling  is 
increased in a liver progenitor cell line in the absence of ADAM10 activity. However, the 
consequences of the increased activation of this pathway need to be clarified in future 
experiments.  ADAM10-mediated  regulation  of  the  hepatocyte  growth  factor  signaling 
pathway is also interesting under the assumption, that deregulation of liver progenitor cell  
differentiation and proliferation leads to a malignant transformation.
The group of Achim Krüger showed that inhibition of ADAM10 by its natural inhibitor 
tissue inhibitor  of metalloproteinase-1 leads to increased metastasis  to the liver  due to 
increase hepatocyte growth factor signaling indicating that ADAM10 may also play a role 
in the metastatic niche in the liver [124, 132]. It might be interesting to further evaluate 
the role of ADAM10 in the hepatocyte growth factor signaling pathway in liver tumor and 
metastases.
Another interesting substrate of ADAM10 is CD44. CD44 is a receptor for osteopontin, 
that was recently shown to drive progenitor cell proliferation and fibrosis [133, 134] We 
noticed that staining for CD44 in ADAM10∆hep/∆ch mice is more prominent than in control 
animals.  In vitro studies will give more insight if CD44 signaling is responsible for liver 
progenitor cell proliferation.
TGFβ signaling is increased in fibrotic liver disease. We could show that ADAM10∆hep/∆ch 
mice also have elevated levels of TGFβ ligands. To investigate if the increase of TGFβ2 also 
effects liver progenitor cells, e.g. transition to a more mesenchymal phenotype, we stimu-
lated BMOL cells with rhTGFβ2 in the presence and absence of an ADAM10 inhibitor. 
Phosphorylation  of  Smad2 is  increased  after  stimulation and even further  increased  if 
ADAM10 is inhibited. We will perform qRT-PCR tests to examine downstream targets 
of ADAM10-regulated TGFβ2 signaling in liver progenitor cells.
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4.3 ADAM10 in two liver damage models inducing different repair 
mechanisms
We showed that ADAM10 is involved in liver progenitor cell-mediated liver regeneration. 
To analyze whether ADAM10 also plays a role in liver regeneration by hepatocyte prolifer-
ation we made use of a carbon tetrachloride (CCl4) induced damage model. In first results 
we see that control and ADAM10-deficient animals respond to CCl4 administration and 
show elevated alanine transaminase levels immediately after treatment. Contrary to what 
we observe in the strong phenotypes of ADAM10∆hep/∆ch mice, alanine transaminase levels 
returned to  normal  in  2  weeks  after  the  last  dose  of  CCl4 independent  of  ADAM10 
expression.  A more  detailed evaluation is  needed,  but  the,  so  far,  acquired data  point 
towards a negligible role of ADAM10 in hepatocytic proliferation dependent liver regen-
eration.
Additionally, we plan to feed the mice with a choline-deficient, ethionine-supplemented 
(CDE) diet leading to chronic liver injury with a subsequent liver progenitor cell-depend-
ent  regeneration  [135].  ADAM10∆hep/∆ch mice,  as  discussed in  chapter  3.2,  showed the 
observed phenotype only in 30-50% of the offspring. By feeding mice with the CDE-diet 
we will subject all mice, KO and WT, to the same injury and induce activation of liver 
progenitor cells in all animals. This allows for direct comparison in liver progenitor cell-
driven regeneration in animals with or without ADAM10. We expect that proliferation in 
the liver progenitor cell-response in ADAM10∆hep/∆ch  mice is increased compared to con-
trols. 
Original  necrotic  damage and fibrosis  might still  be  interfering with induced damage. 
Thus,  we bred inducible  conditional  KO-mice.  Unfortunately,  the first  chosen mouse 
strains with tetracycline-inducible ADAM-10 deletion in hepatocytes did not deliver the 
desired penetrance (see Supplementary Figure 2 for the basic principle of tetracycline-in-
ducible deletion and Supplementary Figure 3). We will therefore replace the doxycyline-
inducible Cre-recombinase with a tamoxifen-inducible Cre-recombinase under an albu-
min promoter (for a basic principle of tamoxifen-induced recombination see Figure 4.2) 
[136]. But, as  alb is  not expressed in progenitor cells,  these experiments result only in 
information about involvement of hepatocytic ADAM10 in liver progenitor cell-driven 
liver regeneration. In a recent report it was described that hepatocytes can dedifferentiate 
after injury to progenitor cells and later, after the chronic injury subsided, differentiate 
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back  to  functional  liver  cells  [137].  We  can  investigate  in  the  conditional  KO-mice 
whether the process of hepatocytic dedifferentiation to progenitor cells in chronic liver 
damage relies on ADAM10. 
Figure 4.2: Tamoxifen-inducible Cre-recombinase
A: Schematic of the tamoxifen-inducible Cre-ERT2 system. Under unstimulated conditions the Cre-recombinase is 
located  in  the  cytoplasm.  Once  tamoxifen  binds  to  the  estrogen-receptor  fused  to  the  Cre-recombinase  the  
complex translocates to the nucleus and mediates site specific recombination 
Another option to follow up on our findings on ADAM10 in liver progenitor cells is to 
knock-out ADAM10 specifically in adult hepatic progenitors. A suitable Cre-recombinase 
for these experiments is Foxl1-Cre which was shown to be active in adult progenitor cells 
but not in fetal hepatoblasts [138]. We can then examine in an CDE-diet model if loss of 
ADAM10 on liver progenitor cells is sufficient to get prolonged liver progenitor cell pro-
liferation after chronic damage. As a proof of principle, treatment with adenoviral admin-
istered ADAM10 should rescue the phenotype.
It has been proposed that fibrotic and cirrhotic livers are often leading to development of 
hepatocellular  carcinomas  [31].  Lack  of  ADAM10 leads  in  our  model  to  an increased 
fibrosis in an liver progenitor cell-dependent damage repair, and inhibition of ADAM10 
leads to increased liver metastases but it is also found upregulated in hepatocellular car-
cinomas  [63, 132]. These findings seem to exclude each other, but one should consider 
that hepatocellular carcinoma can also form without preceding cirrhosis. Nonetheless, it 
will be telling if, how and what kind of tumors develop in ADAM10∆hep/∆ch  mice.
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4.4 Regulation of ADAMs through substrate selectivity
This study and others show that ADAMs can regulate many different and even opposing 
signals. It is therefore essential to understand mechanisms that target ADAMs to specific 
substrates. Proteins with multi-transmembrane domains are discussed to be facilitators of 
this process, for example inactive members of the rhomboid family [139].
Another family of multi-pass transmembrane proteins are tetraspanins [140]. Recent stud-
ies showed interactions between members of the ADAM family and members of the tet-
raspanin family [79, 141]. We thus want to examine the potential of select tetraspanins to 
inf luence ADAMs in their substrate selection. Our hypothesis is that tetraspanins gather 
proteases and substrates in membrane regions like tetraspanin-enriched microdomains. In 
preliminary experiments we see an interaction between the investigated tetraspanins and 
ADAMs and a trend that expression of different tetraspanins leads to ADAMs favoring dif-
ferent substrates (Supplementary Figure 4,  Supplementary Figure 5,  Supplementary Fig-
ure 6). These findings are an excellent start for a more detailed future research on the 
mechanism by which tetraspanins bring together ADAMs and their substrates. 
Figure 4.3: Tetraspanins might influence target selectivity of ADAM17 in PKC dependent shedding
PKC activation through either G-protein-coupled receptor (GPCR) signaling or PMA leads to shedding of ADAM17 
substrates.  We hypothesize  that  substrate-selectivity  will  be  influenced by  members  of  the  tetraspanin  family. 
Besides activating ADAM17, PKC is also known to interact with tetraspanins and ADAM17 substrates [0, 140].
In future investigations we will, with the help of markers for membrane regions like chol-
eratoxin B-FITC, examine membrane localization in more detail. 
We  would  finally  also  like  to  investigate  tetraspanin-mediated  substrate-selectivity  in 
regard to physiological processes, especially in the liver. It has been shown that co-expres-
sion of CD9 leads to an increase of pro-heparin binding-epidermal growth factor and pro-
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amphiregulin,  both  epidermal  growth  factor  receptor  (EGFR)  ligands,  and  thereby 
enhanced juxtacrine signaling [142]. EGFR signaling is crucial in the liver with functions 
from  hepatoprotection  to  hepatocarcinogenesis  and  ADAMs  are  known  sheddases  of 
EGFR ligands [143]. Tspan8 is upregulated in heaptocellular carcinoma and especially in 
intrahepatic metastases [144]. Future analysis will have to show if Tspan8 is connected to 
increased amounts of shed ADAM substrates  found in hepatocellular carcinoma such as 
amphiregulin.
We therefore think that by following up on the tetraspanin-ADAM connection we will 
gain crucial insights into the intricate regulatory network that balances ADAM-activity.
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4.5 Conclusion
Our experiments describe for the first time a potentially essential function of ADAM10 in 
regulating proliferation in adult liver progenitor cells and hence hepatic stellate cell activa-
tion and the progression of liver fibrosis in chronic liver injury. We define ADAM10 as a 
novel major key player in murine liver tissue homeostasis (Figure 4.4). 
We are confident,  that  our findings  will  aid  greatly  in  developing new treatments  for 
fibrosis and cirrhosis. Upregulation of ADAM10 on a transcriptional level by retinoic acids 
has been shown to result in an increased ADAM10 activity [145]. A recent clinical phase II 
study demonstrated that these observation can be also confirmed in human patients suffer-
ing from Alzheimer's disease. After oral treatment with acitretin cleavage of amyloid pre-
cursor protein at the ADAM10 cleavage site was increased [146]. If the therapy would be 
transferable to liver disease, chronic proliferation of liver progenitor cells could become 
treatable. On the other hand, transient inhibition of ADAM10 could be used to enhance 
liver regeneration.
Figure 4.4: Loss of ADAM10 leads to continued LPC proliferation in chronic liver injury
Schematic of the findings described in this study. Hepatocyte necrosis in chronic liver injury leads to activation and 
proliferation  of  the  liver  progenitor  cell  (LPC)  compartment.  LPCs  then  activate  hepatic  stellate  cells  (HSC)  
resulting in deposition of extracellular matrix. Although the damage is repaired by differentiation of LPCs to mature  
hepatocytes, LPC proliferation continues, HSC stay activated, and continued deposition of ECM causes fibrosis.
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6.1 Supplementary Information
6.1.1 Supplementary Materials
6.1.1.1 Chemicals
Dulbecco's modified Eagle medium (DMEM) Sigma-Aldrich, Steinheim, Germany
Polyethylenimine Polysciences, Eppelheim, Germany
Coelenterazine Promega, Mannheim, Germany
6.1.1.2 Primers and oligonucleotides
Supplementary Table 1. Primers for DNA inserts
Target Forward Primer (5'-3') Reverse Primer (5'-3') Annealing 
Temperature
hTspan8 (for 
pTRIPZ)
GCCA  ↓  CCGGT  GCCACCATGGCAG
GTGTGAGTG
CTTA  ↓  CGCGT  ACTCACAAGTCCTCTTC
AC
54°C/>72°C
hCD9 (for 
pTRIPZ)
CGCGCA  ↓  CCGGT  GCCACCATGCC
GGTCAAAGGAGGC
CCAGCGATA  ↓  CGCGT  CCTGCA  ↓  GG  GA
CCATCTCGCGGTTCC
56°C/>72°C
hCD9 (for 
pENTR4)
CGTCGAGC  ↓  GGCCGC  ATGCCGGT
CAAAGG
GACTGCAGC  ↓  TCGAG  TCGACCATCTCG
CGGT
44°C/>72°C
hCD81 (for 
pTRIPZ)
CGACCGCA  ↓  CCGGT  GCCACCATG
GGAGTGGAGGGCTGCAC
CCAGCGATA  ↓  CGCGT  CCTGCA  ↓  GG  GTA
CACGGAGCTGTTCC
56°C/>72°C
hCD81 (for 
pENTR4)
CGTCGAGC  ↓  GGCCGC  ATGGGAGT
GGAGGG
GACTGCAGC  ↓  TCGAG  TCGTACACGGAG
CTGTT
44°C/>72°C
hADAM10 
(for pENTR4)
ATCATCG  ↓  TCGAC  ATGGTGTTGCT
GAGAGTGTTAATTCTGCTC
ATCATCGC  ↓  GGCCGC  AAGCGTCTCATG
TGTCCC
72°C
hADAM17 
(for pENTR4)
CATGC  ↓  GGCCGC  CACCATGAGGC
AGTCTCTC
CGACGGG  ↓  TCGAC  CGGCACTCTGTTTC
TTT
45°C/>72°C
Supplementary Table 2. Oligonucleotides
5'-3' Sequence
3x HA insert sense ↓  GG  ATACCCGTATGACGTCCCGGATTACGCTTACCCGTATGACGTCCCGGATTACGC
TTACCCGTATGACGTCCCGGATTACGCTTAAA  ↓  
3xHA insert antisense ↓  CGCG  TTTAAGCGTAATCCGGGACGTCATACGGGTAAGCGTAATCCGGGACGTCAT
ACGGGTAAGCGTAATCCGGGACGTCATACGGGTATCCTGCA  ↓  
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6.1.1.3 Primer
Supplementary Table 3. Primers for genotyping and genomic DNA
Target Forward Primer (5'-3') Reverse Primer (5'-3') Expected 
bandsize
rtTA CCATGTCTAGACTGGACAAGA CTCCAGGCCACATATGATTAG 600 bp
6.1.1.4 Cell lines
Supplementary Table 4. Cell lines and respective culture media
Cell line Source of cells Culture medium Source Remarks
HEK293-T Human embryonic 
kidney
Dulbecco's modified Eagle Medium (DMEM) 
+ 10% FCS
DSMZ
6.1.1.5 Mice
Supplementary Table 5. Mice
Mouse line Source Reference
B6.Tg(Cebpb-rtTA2S*S2)1Bjd EMMA:EM:00404 [147]
B6.Cg-Tg(tetO-cre)1Jaw/J Paul Saftig (University Kiel, Germany) [148]
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6.1.2 Supplementary Methods
6.1.2.1 Breeding of mice and genotyping PCR conditions
Supplementary Figure  1: Breeding schematic  for  doxycycline-inducible conditional  ADAM10 knockout in 
hepatocytes.
Genotypes used in experiments are marked by a thick black frame. Color schemes are equivalent to the ones used  
in bar charts for the respective genotype. 
P:  parental  generation;  F1:  first  generation  (progeny  of  P);  F2:  second  generation  (progeny  of  F1);  F3:  third 
generation (progeny of F2)
Supplementary Table 6. rtTA PCR conditions
Step Temperature Time Cycles
Initial Denaturation 95°C 2' 1
Denaturation 95°C 30''
30Annealing 58°C 30''
Elongation 72°C 1'
Final Elongation 72°C 10' 1
Storage 4°C ∞ 1
For detailed information on genotyping primers please refer to Supplementary Table 3
6.1.2.2 Doxycycline administration
Doxycycline was added to regular lab chow at a concentration of 1 g/kg (Ssniff, Soest, 
Germany).  Mice  were  fed  ad  libitum.  Considering  that  doxycycline  is  photosensitive, 
chow was changed two times per week to ensure a constant dosage of doxycycline. Mice 
were sacrificed after at least 4 week of doxycycline administration.
6.1.2.3 Generation of stable cell lines
HEK293T cells were transfected with plasmids encoding for doxycycline-inducible tet-
raspanins (Tspan8, CD9, and CD81, see Supplementary Table 6) as well as a puromycine 
resistance as described in 6.1.2.4. Cells were selected for plasmid uptake by culturing them 
in the presence of 2 µg/ml puromycine. Cells were tested for tetraspanin expression in the 
presence and absence of 80 µg/ml doxycycline by immunoblotting of cell lysates.
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6.1.2.4 Luciferase complementation assay
Luciferase complementation assay was performed as described previously  [149]. Brief ly, 
HEK293T cells were seeded at a density of 1x105 cells/ml in 500 µl/well of a 24-well plate. 
The following day, cells were transfected with plasmid DNA at a ratio of 1:3 to the trans-
fection agent Polyethylenimine. Cells always received a combination of two plasmids, one 
coding for the C-terminal part of Gaussia princeps luciferase and one coding for the N-ter-
minal part of Gaussia princeps luciferase, each fused to a protein of interest or as an empty 
control. On the second day after transfection, cells were washed, lysed in 100 µl passive 
lysis buffer (#E1941, Promega, Mannheim, Germany) for 15 min at RT, and then trans-
ferred, in triplicates of 20 µl each, to a white 96-well bioluminescence plate. Biolumines-
cence was detected using a Glomax plate injector system (Promega, Mannheim, Germany) 
by dispensing 50 µl substrate17 per well and measuring luminescence for ten seconds after a 
two second premeasurement delay. 
Normalized luciferase ratio (NLR) and standard deviation of NLR were calculated as fol-
lows:
GOI = GOI1-pSPICA-C1/GOI2-pSPICA-C2
C1    = GOI1-pSPICA-C1/pSPICA-C2
C2   = pSPICA-C1/GOI2-pSPICA-C2
NLR = 
GOI
C1+C2
σNLR = √( NLRδGOIδ ∗ GOIσ )2+( NLRδC1δ ∗ C1σ )2+( NLRδC2δ ∗ C2σ )2
= √( 1C1+C2∗ GOIσ )2+( GOI(C1+C2)2∗ C1σ )2+( GOI(C1+C2)2∗ C2σ )2
NLRδ
xδ = partial derivative of the NLR equation with respect to GOI, C1 or C2, respectively
σGOI; σC1; σC2: standard deviation of GOI, C1 or C2, respectively
A NLR above 3.5 was considered a specific interaction.
6.1.2.5 Alkaline phosphatase-shedding assay
Shedding of alkaline phosphatase (AP)-tagged substrates was carried out as specified by 
Inoue et al  [150]. In short, the in 6.1.2.3 described cell lines or parental HEK293T cells 
17 2.36 µM Coelenterazine (diluted in PBS)
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were treated with doxycycline and transiently transfected with plasmids encoding for AP-
tagged ADAM17 substrates (TGFα, TNFα, IL-6R, and IL-1R2). Cells were then stimu-
lated with phorbol 12-myristate 13-acetate (PMA) to induce ectodomain shedding. In a 
variation of the experimental setup histamine-stimulated shedding was investigated. To 
this end cells were additionally transiently transfected with the histamine H1 receptor and 
were stimulated with histamine instead of PMA. AP-activity in the cells and in the super-
natant was measured by conversion of  colorless  para-nitrophenolphosphate substrate  to 
yellow para-nitrophenol directly after substrate addition and one hour after substrate addi-
tion. To determine the relative amount of shed AP-substrate in comparison to the unstim-
ulated controls (AP-release) the following calculations were used: 
ΔOD405 = OD4051h – OD4050h
AP-Substrate in conditioned media (CM) (%) = 
∆OD405 CM
∆OD405 CM+∆OD405 Cell
AP-release (%) = AP-Substrate in CM under stimulated conditions - AP-Substrate in CM 
under vehicle-stimulated conditions
For a schematic of the experimental setting please refer to Supplementary Figure 5 A+B 
and Supplementary Figure 6 A.
6.1.2.6 Generation of inserts for cloning
cDNAs for the proteins of interest were amplified by PCR from template plasmids or 
from cellular cDNA using the primers indicated in Supplementary Table 1. PCR mix was 
prepared as follows:
50 ng template DNA
10 µl 5x HF or GC Buffer
1 µl dNTPs (10 mM)
1.5 µl 5' Primer (10 µM)
1.5 µl 3' Primer (10 µM)
0.5 µl   Phusion Hot Start II Polymerase
adjust to 50 µl with ddH2O
For amplification by PCR a two step protocol was chosen:
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Supplementary Table 7. PCR conditions for cloning
Step Temperature Time Cycles
Initial Denaturation 98°C 5' 1
Initial Annealing see Supplementary
Table 1
20'' 1
Initial Elongation 72°C 25'' – 90'' 1
Denaturation 98°C 20''
30
Elongation 72°C 25'' – 90''
Final Elongation 72°C 3' 1
Storage 4°C ∞ 1
PCR products were purified before being subjected to restriction digestion.
6.1.2.7 Purification of DNA fragments
PCR products were loaded on SafeRed (iNtRON Biotechnologies,distributed by HISS 
diagnostics, Freiburg, Germany) supplemented agarose gels18 and separated in an electric 
field. The according DNA bands were excised with a scalpel under UV light and trans-
ferred to a 1.5 ml tube. Per 100 mg gel 400 µl GMII19 was added and per µg DNA 5 µl 
GMI20, but at least 15 µl GMI. Samples were incubated at 50°C under constant agitation 
until the gel was dissolved. After centrifugating for 1 min at 13 000 rpm, supernatant was 
discarded, the pellet was washed twice in GMIII21 , and dried at 37°C for at least 10-15 
min. DNA was resuspended in TE-Buffer22 at 55°C and transferred to a fresh tube.
6.1.2.8 DNA digestion of vector and PCR product
Vector and PCR product were digested with the same restriction enzymes (listed in Sup-
plementary Table 8 and Supplementary Table 9, all enzymes were from ThermoScientific 
except SbfI (NEB)) at the according temperature for 1 h. The reaction was stopped by 
incubating the samples for 20 min at 65°C. PCR products were then purified as described 
in 6.1.2.7. Vectors were directly used for Ligation.
6.1.2.9 Annealing and phosphorylation of oligonucleotides
Oligonucleotides were annealed in NEBuffer 4 by incubation at 95°C for 5 min and then 
slowly  cooling  the  samples  down  to  4°C.  Afterwards  oligonucleotides  were  phos-
phorylated for 30 min at 37°C in T4 ligasebuffer using Polynucleotide Kinase (ThermoS-
18 Agarose-gel: 1-2.5% agarose, 40mM Tris, 1,14% acidic acid, 1 mM EDTA; add 0.05% SafeRed
19 GMII: 6 M guanidinium thiocyanate, 0.1 M Tris-HCl, 44 mM EDTA, 2.6% Triton X-100
20 GMI: 5 g diatomaceous earth; adjust volume to 25 ml with ddH2O and add 25 µl HCl (37%)
21 GMIII: 0.1 NaCl, 10 mM Tris, 2.5 mM EDTA, 50% EtOH
22 TE-Buffer: 5 mM Tris, 0.1 mM EDTA
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cientific, Darmstadt, Germany). The reaction was stopped by heating the samples to 70°C 
for 10 min.
6.1.2.10 Ligation of DNA
Purified,  digested PCR products  or  oligonucleotides  were ligated into digested vector 
DNA with T4 DNA Ligase (ThermoScientific, Darmstadt, Germany) according to the 
manufacturer’s instructions.
Amount of used insert (3-times excess over vector) per 100 ng vector was calculated as fol-
lows:
kb Insert
kb vector
∗100ng∗3 = x ng Insert
Supplementary Table 8. Conventional plasmids
Vector backbone Insert Restriction Sites Specifications
pTRIPZ hTspan8-myc AgeI/MluI Doxycycline-inducible, 3' myc-tag
pTRIPZ hCD9-3xHA AgeI/SbfI/MluI Doxycycline-inducible, 3' 3xHA-tag
pTRIPZ hCD81-3xHA AgeI/SbfI/MluI Doxycycline-inducible, 3' 3xHA-tag
Plasmids encoding for AP-TGFα, TNFα-AP, AP-IL-6R, and AP-IL-1R2 were kind gifts 
of D. Floss and I. Lorenzen (University Kiel, Germany).
6.1.2.11 Homologous recombination (Gateway® cloning)
Previously generated Entry-Vectors, containing attL sites, and Destination-Vectors, con-
taining attR sites,  were incubated for  1 hour with LR Clonase® II (life technologies, 
Darmstadt, Germany) at 25°C. The reaction was stopped by adding proteinase K, incub-
ated for 10 min at 37°C, and was then ready-to-use for bacterial transformation. Used 
Entry-Vectors and Final Vectors are listed in Supplementary Table 9 and Supplementary
Table 10, respectively. 
Supplementary Table 9. Gateway Entry-Vectors
Vector backbone Insert Restriction Sites
pENTR4 hADAM10 SalI/NotI
pENTR4 hADAM17 NotI/SalI (compatible to XhoI cleavage site)
pENTR4 hCD9 NotI/XhoI
pENTR4 hCD81 NotI/XhoI
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Supplementary Table 10. Gateway Final-Vectors
Destination Vector Insert Specifications
pSPICA-C1 hADAM10 3'-fused to G. princeps luciferase part 1
pSPICA-C2 hADAM10 3'-fused to G. princeps luciferase part 1
pSPICA-C1 hADAM17 3'-fused to G. princeps luciferase part 1
pSPICA-C2 hADAM17 3'-fused to G. princeps luciferase part 1
pSPICA-C1 hCD9 3'-fused to G. princeps luciferase part 1
pSPICA-C2 hCD9 3'-fused to G. princeps luciferase part 1
pSPICA-C1 hCD81 3'-fused to G. princeps luciferase part 1
pSPICA-C2 hCD81 3'-fused to G. princeps luciferase part 1
pSPICA-C1 hTetraspanin8 3'-fused to G. princeps luciferase part 1
pSPICA-C2 hTetraspanin8 3'-fused to G. princeps luciferase part 1
pDONR233-Tspan8 as well as the pSPICA-C1 and pSPICA-C2 destination vectors were 
a kind gift from Y. Jacob (Institute Pasteur, Paris, France).
6.1.2.12 Chemical competent bacteria
Bacteria were grown ON in 2ml LB-Medium23. 1 ml of the ON culture was transferred 
to 150 ml fresh medium and was allowed to grow at 37°C with gentle agitation until an 
OD600 of 0.6 was reached. Bacteria were spun down at 5 000 rpm for 10 min and the pellet 
was resuspended in 15 ml TSB24. Bacteria were kept on ice for 10 min. They were then 
aliquoted and stored at -80°C.
6.1.2.13 Transformation of bacteria
5 µl of a homologous recombination or of a ligation reaction were added to diluted KCM 
buffer25 in  a  total  volume of  50 µl  and mixed with  50 µl  chemically  competent  E.coli 
DH5α. The mixture was incubated on ice for 30 min, bacteria were heat-shocked for 1 
min at 42°C and then left to sit on ice for 1-2 minutes to close the pores. 500 µl LB-Me-
dium was added to the bacterial suspension. The mix was incubated for 1 hour at 37°C 
with gentle agitation and plated completely or partially on LB-Agar26 plates containing the 
appropriate antibiotics using sterile glass beads. Plates were incubated ON at 37°C.
23 LB-Medium (1l): 10 g Tryptone, 5 g yeast extract, 10 g NaCl; adjust to 1 l with ddH2O and autoclave
24 TSB: 10 g Tryptone, 5 g yeast extract, 10 g NaCl, 5% DMSO, 10 mM MgCl2, 10 mM MgSO4, 10% PEG 4000; adjust to 1 l 
with ddH2O and sterilize by filtration
25 KCM buffer (5x): 0.5M KCl, 0.15 M CaCl2, 0.15 MgCl2
26 LB-Agar: 15 g/l Agar in LB-Medium
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6.1.2.14 Amplification of plasmids with CopyCutter™ bacteria
For plasmids coding for ADAM17 and ADAM10, CopyCutter™ bacteria (Epicentre, dis-
tributed by Biozym, Hessisch Oldendorf, Germany) were used for plasmid amplification. 
CopyCutter™ bacteria are designed to amplify a significantly lower copy number of vec-
tors.  Copy  number  can  be  raised  by  incubation  for  a  short  time  in  the  presence  of 
CopyCutter Induction Solution. This technology allows for the amplification of unstable 
or toxic DNA sequences.
The first steps were as described in 6.1.2.13. A single colony was picked from the plate and 
used to inoculate an ON culture in 5 ml LB-medium. Bacteria were then again spread on 
agar-plates and incubated ON. These bacteria were pooled and used to inoculate a new 
culture in LB-medium with antibiotics and CopyCutter Induction Solution (Biozym Sci-
entific, Hessisch Oldendorf, Germany) that had a starting OD600 of 0.2. Cultures were 
incubated at 37°C under constant agitation for 4 h and plasmid DNA was then isolated 
with the Nucleobond® XtraMidi kit (Machery-Nagel,  Düren, Germany) according to 
the manufacturer’s instructions.
6.1.2.15 Plasmid isolation
For plasmid isolation a single colony was inoculated in 2 ml antibiotic-supplemented LB-
medium and incubated ON at 37°C and constant agitation. Bacteria were pelleted, resus-
pended in SolutionI27, and lysed in SolutionII28. Lysis was stopped by adding SolutionIII29, 
samples were centrifuged, DNA precipitated, washed in 70% EtOH, and dried at RT. 
DNA was dissolved in TE-Buffer by vortexing.
To receive large amounts of plasmid DNA, 100 ml bacterial cultures were inoculated and 
plasmid DNA was isolated with the Nucleobond® XtraMidi kit (Machery-Nagel, Düren, 
Germany) according to the manufacturer’s instructions.
6.1.2.16 Quantification of nucleic acids and sequencing
DNA concentrations and purity were analyzed spectrophotometrically by a Nano-Drop 
photometer (distributed by PeqLab, Erlangen, Germany). Sequencing was performed by 
GATC Biotech (Constance, Germany) using Sanger-sequencing.
27 Solution I: 50 mM Glucose, 25 mM Tris-HCl, 10 mM EDTA, 60 µg/ml RNaseA
28 Solution II: 0.2 mM NaOH, 1% SDS
29 Solution III: 3 M KAc, 11.5 % acetic acid
84
6 Appendix
6.1.3 Supplementary Figures
Supplementary Figure 2: Tetracyline regulated Cre system
Schematic of the Tet-off and the Tet-on systems. Expression of the target gene is under the transcriptional control  
of a tetracycline-responsive promoter element (TRE). The Tet-Off system relies on the activity of a tetracycline-
controlled transactivator (tTA) binding to the TRE and activating transcription. In the presence of Tetracycline or  
doxycycline, a derivative of tetracycline, tTA can not bind and transcription is inactive. Contrary, in the Tet-On 
system the presence of doxycycline leads to the binding of the reverse tetracycline-controlled transactivator (rtTA) 
to the TRE and hence transcription of the target gene. The tTA or rtTA expression can be driven by specific  
promoters to only target select cells or tissues [0]. In our case the target gene under control of the TRE is a Cre-
recombinase.
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Supplementary Figure 3: No efficient recombination of floxed ADAM10 with the Lap-rtTAxTRE-Cre System
A: Deletion PCR for ADAM10 from genomic DNA from the liver. The band at approximately 2000 bp results from 
floxed ADAM10. The expected bandsize for ADAM10 that is successfully recombined and therefore has a deletion 
in Exon2 is between 500 and 750 bp. Asterisk marks low bp band that probably consists of primerdimers.  B: 
ADAM10 protein expression does not differ in total liver extracts of ADAM10 fl/fl  x TRE-Cre mice with or without 
Lap-rtTA as shown by this Immunoblot. Solid arrowhead marks pro-form of ADAM10. Open arrowhead marks  
mature form of ADAM10 C: Liver weight and spleen weight is not altered in mice carrying the Lap-rtTA transgene 
compared to their littermate that do not carry that transgene.
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Supplementary Figure 4: Interaction of Tspans and ADAMs
A: Schematic  of  the  luciferase-based  protein  complementation  assay.  Both  proteins  of  interest  (A+B)  are  C-
terminal tagged with one out of two inactive fragments of Gaussia princeps luciferase (C1; C2). If the proteins of 
interest are in close proximity, the two inactive luciferase fragments can complement each other to a functional  
enzyme. (modified from [149]) B: The normalized luciferase ratio (NLR) for the investigated interaction partners is 
calculated by dividing the relative light units emitted by cells expressing both proteins of interest by the sum of the  
luminescence in the controls. (modified from  [149])  C: Interaction between Tetraspanin8 and the ADAM-family 
members 10 and 17. The assay was performed with the aforementioned method in Hek293T cells. The depicted 
results are representative of at least three independent experiments. The default NLR threshold at 3.5 is marked  
by a red line. (n=3) D: Evaluated interaction between Tetraspanins CD9 and CD81 and ADAM17. The assay was 
performed with the aforementioned method in Hek293T cells. The depicted results are representative of at least  
three independent experiments. The default NLR threshold at 3.5 is marked by a red line. (n=3)
Data represent the NLR ± standard deviation.
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Supplementary Figure 5: Tetraspanins regulate substrate specificity in PMA-stimulated ADAM17-dependent 
shedding
A:  Principle  of  the  alkaline  phosphatase  (AP)-Shedding  assay  shown  in  schematic.  Hek293T  cells  transiently  
expressing  AP-tagged  substrates  of  ADAM17  are  stimulated  by  agents  that  induce  ectodomain  shedding  by 
ADAM17. The AP-tagged extracellular domain of the substrate is hence released to the supernatant. Shedding can  
be quantified by colorimetric measurement of AP activity in the conditioned medium as well as in the remaining  
cells based on the AP-dependent conversion of para-Nitrophenolphosphate (p-NPP) to yellow para-Nitrophenol (p-
NP). The relative amount of shed substrate is calculated by dividing the measured absorbance in the conditioned 
medium by the sum of the measured absorbance in the conditioned medium and the cells. (modified from [150]) B: 
Schematic of experimental setup used in C. Hek293T cells transiently expressing AP-tagged ADAM17 substrates  
were stimulated with PMA to induces ADAM17-dependent shedding. C: Fold change in PMA stimulated shedding in 
cells expressing specified Tetraspanins compared to cells not expressing these specified Tetraspanins. Values were  
beforehand normalized to unstimulated cells to account for constitutive shedding. (n.d. = not detected) (n=1-3)
Data represent the mean ± standard error of the mean.
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Supplementary  Figure  6:  Tetraspanins  regulate  substrate  specificity  in  histamine-stimulated  ADAM17-
dependent shedding
A: Schematic of experimental setup used in B. Hek293T cells transiently expressing AP-tagged ADAM17 substrates  
and the Histamine H1 Receptor were stimulated with Histamine to induces ADAM17-dependent shedding. B: Fold 
change in Histamine stimulated shedding in cells expressing specified Tetraspanins compared to cells not expressing 
these specified Tetraspanins. Values were beforehand normalized to unstimulated cells to account for constitutive  
shedding. (n.d. = not detected) (n=1-3)
Data represent the mean ± standard error of the mean.
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6.2 Abbreviations
For this work the guidelines and general rules of the International System of Units were 
adhered to, including the rule that spaces should be used as a thousands separator.
°C Degree celsius
aa Amino acid
ADAM A disintegrin and metalloprotease
ALT Alanine transaminase
AP Alkaline Phosphatase
APS Ammonium persulfate
BMOL Bipotential murine oval cell line
bp Basepairs
BSA Bovine serum albumin
CCL2 Chemokine (C-C motif) ligand 2
CD Cluster of differentiation
CDE Choline-deficient, ethionine enriched
cDNA Complementary deoxyribonucleic acid
CK19 Cytokeratin 19
CM Conditioned medium
CXCL (C-X-C- motif) ligand
Cxcr4/7 C-X-C chemokine receptor type 4/7
DMEM Dulbecco's modified eagle medium
DMSO Dimethylsulfoxide
DNA Deoxyribonucleic acid
dNTP Deoxy nucleoside triphosphate
e Embryonic day of gestation
ECM Extracellular matrix
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
ELISA Enzyme-linked Immunosorbent Assay
ER Estrogen receptor
ERK Extracellular-signal-regulated kinase
EYFP Enhanced yellow fluorescent protein
FCS Fetal calf serum
FITC Fluorescein isothiocyanate 
g Gram
GFP Green fluorescent protein
h Hours
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H&E Hematoxylin and Eosin
HGF Hepatocyte growth factor
HRP Horseradish peroxidase
HSC Hepatic stellate cells
ICD Intracellular domain
iCLIP Intramembrane-cleaving protease
IGF-II Insulin-like growth factor-II
IL Interleukin
IL-1R2 Interleukin-1 receptor 2
IL-1RA Interleukin-1 receptor antagonist
IL-6 Interleukin-6
IL-6R Interleukin-6 receptor
IκB Inhibitor of κB
kDa kilo Dalton
kg kilogram
KO Knock-out
l Liter
Lap Liver activator protein
Lgr Leucine-rich repeat-containing G-protein coupled receptor
LPC Liver progenitor cell
M molar
mg Milligram
min Minutes
ml Milliliter
mM Millimolar
mm Millimeter
MMP Matrix metalloproteinase
mRNA Messenger ribonucleic acid
Mrp2 Multidrug resistence-associated protein 2
MT1-MMP Membrane type 1 matrix metalloprotease
MTT 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide
NFκB Nuclear factor κB
NLR Normalized Luciferase Ratio
nm Nanometer
OD Optical density
ON Over night
p-NP para-Nitrophenol
p-NPP para-Nitrophenolphosphate
panCK panCytokeratin
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PAS Periodic-acid-Schiff stain
PBS Phosphate buffer saline
PCR Polymerase Chain Reaction
PKC Protein kinase C
PMA Phorbol 12-myristate 13-acetate
PMSF Phenylmethylsulfonylfluorid
qRT-PCR quantitative real-time polymerase chain reaction
RFP Red fluorescent protein
RH Relative humidity
RIP Regulated intramembrane proteolyis
RNA Ribonucleic acid
rpm Revolutions per minute
RT Room temperature
rtTA Reverse tetracycline-controlled transactivator
SDS Sodium dodecyl sulfate
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel
sec Seconds
SEM Standard error of mean
SN Supernatant
Spp1 Secreted phosphoprotein 1
TEMED Tetramethylethylenediamine
TGFα/β Transforming growth factor α/β
TGFβRI/II Transforming growth factor β Receptor I/II
TIMP Tissue inhibitor of metalloprotease
TNF Tumor necrosis factor
Tnfrsf12a Tumor necrosis factor receptor superfamily 12a
Tnfsf12 Tumor necrosis factor superfamily 12
TRE Tetracycline-responsive promoter element
Tspan8 Tetraspanin8
tTA Tetracycline-controlled transactivator
TWEAK Tumor necrosis factor-like weak inducer of apoptosis
U Unit
UPL Univeral probe library
V Volt
w/v weight per volume
WT Wild type
αSMA Alpha smooth muscle actin
µg Microgram
µl Microliter
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